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Abstract 
Introduction: It is believed that people affected by schizophrenia, who have a long gap between 
the onset of psychotic symptoms, and the start of treatment have worse outcomes, both in the 
short and long-term. This is called the duration of untreated psychosis hypothesis 
An area where there is limited current research is the effect of the duration of prodromal 
symptoms in people at clinical high risk for psychosis (CHR-P). These prodromal symptoms are 
reported in a majority of those who transition to psychosis, suggesting that they may be 
significant for later outcomes. This study focuses on the timing of the relative onset of attenuated 
psychotic symptoms (APS) and basic symptoms (BS); on the reported duration of BS and APS, 
from participants at CHR-P; and the effects of these on functional outcomes, and on cognition. 
There is a specific hypothesis that APS are a consequence of BS, implying that BS should 
commence before APS. 
Methods: Participants were recruited as part of the Youth mental health, risk and Resilience 
(YouR) study. This is a community-based study, carried out among people aged 16 to 35 in 
Glasgow and Edinburgh, analyzing emerging psychotic symptoms. Data from 134 CHR-P 
participants were analyzed for the duration of APS and BS and these were related to global 
assessment of functioning (GAF), role functioning and social functioning.  Two measures of 
cognition were collected during baseline assessments. An analysis was conducted to compare 
duration of APS and BS symptoms, and to assess the effect of duration on GAF scores, role 
functioning, social functioning and cognition measures.  
Results: There was no significant relationship between BS onset and APS, and in a significant 
percentage of the sample (n = 24, 37.5%) the reported APS onset was prior to BS onset. Only 
CHR-P individuals with long BS showed some evidence for the hypothesized relationship of BS 
preceding APS (n = 13, p = 0.04). Duration of APS and BS showed no significant effects on 
cognition, except for small effects on motor speed and verbal fluency. Duration of prodromal 
symptoms also did not show any significant effects on any of the measures of functioning.  
Discussion: The current study did not support the hypothesis that BS precedes the emergence of 
APS in individuals who are CHR-P. This could have significant implications for current 
conceptions of APS and BS in the prodromal period. A number of factors have been previously  
reported to effect recall of duration of prodromal symptoms, including years of education and 
age at onset of symptoms. No evidence was found of between group differences. These findings 
produce two key questions; how accurate is the hypothesis that APS are a secondary 
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consequence of BS, and are there between group differences previously not considered which 
may affect the difference in reported symptoms. Areas for future research on this topic are 
discussed.   
The implications of the negative findings for functioning and cognition are compared to current 
research into duration of untreated psychosis. The differences in the finding are theorized to be 
linked to two key hypotheses in psychosis; the critical period of psychosis and the 
neurodevelopmental theory of psychosis. Both these theories have time dependent components, 
but current research using duration of prodromal symptoms is limited. Potential implications of 
this study as preliminary evidence for them are discussed.  
 Finally, this study reported significantly longer duration of prodromal symptoms in a non-help 
seeking sample, compared to previous findings conducted on clinical samples. The implications 
of these findings and suggestion for future research are discussed.  
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1 Introduction  
1.1 Schizophrenia prevalence  
Schizophrenia is a chronic mental illness, defined by psychotic experiences of hallucinations and 
delusions, disorganised speech and behaviour, and impaired cognitive abilities (Patel et al., 
2014). Schizophrenia affects 1 in 100 people worldwide (World Health Organization, 2013), and 
onsets in late adolescence to early adulthood. Schizophrenia is more prevalent in men than in 
women (Iacono & Beiser, 1992).  Psychotic experiences are associated with higher levels of 
depression and distress (Heinze et al., 2018). Schizophrenia can be a highly debilitating 
condition and has been shown to lead to poor long term functional outcomes (Green, 2006), 
social isolation (Kalin et al., 2015), and significant decline in physical health (De Hert et al., 
2011). Schizophrenia is associated with decreased life expectancy compared to the general 
population of between 12 – 15 years (Saha et al., 2007). This is also related to elevated suicide 
risk with as many as 10% of those diagnosed with schizophrenia dying from suicide, and as 
many as two to five times that making attempts throughout their lives (Siris, 2001).  
1.2 Stages of schizophrenia progression  
Traditional concepts of schizophrenia progression characterized the progression of 
schizophrenia into four clinical stages; premorbid, prodromal, psychotic and residual/recovery 
(Lieberman et al., 2001).  
The premorbid stage is thought to start as early as in gestation, and generally lasts between one 
to three decades (Avramopoulos, 2018). The premorbid phase is associated with mild non-
specific motor, social and cognitive impairments, and not all those who experience these 
symptoms will progress into later stages (Lieberman et al., 2001).  
The prodromal phase is characterised by a progression from nonspecific behavioural changes to 
the onset of attenuated psychotic symptoms (APS) or basic symptoms (BS) (Lieberman et al., 
2001). APS manifest like full psychotic positive and negative symptoms, but are present to a 
lesser degree by intensity, frequency and/or duration (Yung et al., 2005). BS are subjectively 
experienced disturbances across different domains of perception, thought processing, language, 
and attention (Schultze-Lutter et al., 2007). These are thought to be present between 1 to 5 years 
before the emergence of full psychotic symptoms (Häfner et al., 2003), though the length of this 
period varies across individuals. Significantly, those who do experience sub-threshold 
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symptoms, do not necessarily progress to the third phase (Nelson et al., 2016), and those who 
experience the progressive stage do not always experience APS or BS (Shah et al., 2017).  
The psychotic stage is defined by onset of full psychotic symptoms. These are defined in the 
Diagnostic and Statistical Manual of Mental Disorders (DSM V) as the presence of at least two 
symptoms (hallucinations, delusions, disorganised speech, disorganised or catatonic behaviour, 
or negative symptoms) for at least six months continuously, with at least one month of active 
symptoms associated with social and occupational deterioration (American Psychiatric 
Association, 2013). It is hypothesized that the first two-three years following onset of psychosis 
is associated with significant and rapid deterioration of neurological processes (Birchwood et 
al., 1998). This is called the critical period theory of psychosis, and it is thought that this is the 
period in which effective intervention may control the pathophysiological progression of 
schizophrenia (Sheu et al., 2019). 
 Following first episode psychosis (FEP) the fourth clinical stage is the residual period. This 
stage has a diverse range of outcomes, but is defined by some lingering cognitive and 
symptomatic impairments. During the residual period, individuals often experience relapses, 
which are characterised by acute psychotic exacerbation (Emsley et al., 2013). The variation in 
the outcomes during the residual stage means some people experience multiple relapses, while 
others experience none. 
More recent research on the clinical stages of schizophrenia has focused on the heterogeneity of 
progression (Ruiz-Iriondo et al., 2013). McGorry et al. (2006) proposed that schizophrenia 
progression should instead be viewed through a clinical staging model. Clinical staging models 
are commonly used in general medicine, in areas such as cancer, and rather than focus on 
diagnostic criteria, they instead focus on clinical outcomes and variables (Scott & Henry, 2017).  
The advantage of this approach is it allows for a more precise identification of the stage of the 
condition.  
The model for schizophrenia proposed by McGorry and colleagues (2006) has eight stages; 
stages 0, 1a and 1b all describe progression from increased risk of psychotic experiences to 
moderate attenuated psychotic experiences. Stage 2 describes FEP experiences, and stages 3 a, 
b, c and 4 identify different trajectories of incomplete recovery, incomplete remission from FE, 
singular relapse, multiple relapse, and chronic psychosis, respectively. The difference in this 
model is the emphasis placed on the non-linearity of schizophrenia (McGorry et al., 2018).  
14 
 
1.3 Symptoms of schizophrenia  
The main symptoms of schizophrenia can be divided into three categories; negative symptoms, 
positive symptoms, and disorganised symptoms (Arciniegas, 2015). Initially these sets of 
symptoms were divided into distinct types of schizophrenia, though both could be present in a 
single individual (Crow, 1985).  Type I describes positive symptoms of schizophrenia, and Type 
II describing the negative symptoms, and if individuals reported cognitive impairments. This 
delineation has become less used in more recent research, favouring viewing the symptoms as 
clusters of symptoms, rather than separate types, to more accurately reflect the heterogeneous 
presentation of schizophrenia (Jablensky, 2010). Several studies for example Konopaske & 
Coyle (2015), argue that affective dysregulation should be considered a third separate cluster, 
describing symptoms such as flattening affect, depression, mania, anxiety and impulsivity, 
though this is currently considered as part of the negative symptoms in DSM V (American 
Psychiatric Association, 2013) 
1.3.1 Negative symptoms  
Negative symptoms were noted in early research into schizophrenia, though the precise 
groupings of these symptoms has been frequently changed (Galderisi et al., 2017). More recent 
research, using factor analysis and wider meta-analysis have divided negative symptoms into 
two subgroups: 1) amotivation and 2) diminished expression (Foussias et al., 2014). Amotivation 
describes a cluster of symptoms including inability to feel pleasure (anhedonia), a lack of interest 
in goal directed behaviour (avolition) or socializing (asociality),  or a wider lack of interest in 
daily activities (apathy). Diminished expression is used to group two subtypes of symptoms: a) 
affect flattening, apathetic and unchanging facial expression and limited strength, tone or pitch 
of voice, and b) poverty of speech, a lack of additional unprompted content.  
1.3.2 Positive symptoms  
Positive symptoms describe experiences of hallucinations, delusions, and formal thought 
disorder, though the latter is sometimes considered as a separate third category of symptoms 
(McCutcheon et al., 2019). Hallucinations are defined as sensory perceptions experienced during 
consciousness in the absence of an external stimulus, and are primarily associated with damage 
to the visual system or psychiatric disorders (Rees, 2009). In schizophrenia, hallucinations can 
be experienced through any sensory system, i.e.  visual, auditory, olfactory, gustatory and tactile. 
Delusions  are ideas that are held with conviction by individuals, regardless of evidence or 
plausibility, that cannot be accounted for by a person’s cultural or religious background, or level 
of intelligence (Kiran & Chaudhury, 2009).  
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1.3.3 Thought disorder 
Formal thought disorders describes an impaired capacity to sustain coherent language  (Rivkin 
& Barta, 2017) and describes a number of symptoms, including restricted quantity or significant 
vagueness (poverty of speech), tangentiality, distractibility or sudden loss of association 
(derailment). Other components of thought disorder include repeated, jumbled language 
(schizophasia), repeated word uses of self (perseveration) or others (echolalia), interrupted 
speech (blocking), unconventional word use (word approximations), inventing new words 
(neologisms), substitution of inappropriate word or word mispronunciation (paraphasic error) 
(Rivkin & Barta, 2017). 
1.4 Cognitive deficits in schizophrenia   
There are a wide range of positive and negative symptoms associated with schizophrenia, and 
individuals with schizophrenia can be highly heterogeneous in how they present (Andreasen et 
al., 1990). In comparison, impairment in cognitive deficits is a significantly more stable feature  
(Lieberman et al., 2001).  These cognitive deficits are also found in those who do not transition 
(Sawada et al., 2017). These deficits compared to healthy controls remain even in the remission 
of psychotic symptoms (Settem et al., 2019), and are thought to be a significant contribution to 
the continued low functional outcomes for this group (Green, 2006).  
1.4.1 Attention  
Attention is defined as the cognitive process of selectively focusing on relevant stimuli and 
ignoring other information (Styles, 2006). Attention is not a single process, but consists of  
multiple sub-processes, including the ability to divide attention, selective attention (the ability 
to avoid distraction) and sustained attention (Baddeley, 1998;  Baddeley, Baddeley, Bucks, & 
Wilcock, 2001). Meta-analysis has found that individuals with schizophrenia show deficits 
across all of these areas (Fioravanti et al., 2005), including in participants identified as being at 
clinical high risk for psychosis (CHR-P). Attention deficits in FEP and schizophrenia have been 
linked to poorer social and role functioning (Fu et al., 2017; Torgalsbøen et al., 2015) 
1.4.2 Working memory  
Working memory provides temporary storage and manipulation of sensory input which is 
involved in language comprehension, reasoning, and learning (Baddeley, 1992). Working 
memory impairment in individuals with schizophrenia has been of interest to research in 
cognitive deficits. In a meta-analysis of over 200 studies, working memory deficits in 
visuospatial and executive control were demonstrated robustly, though with significant group 
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differences based on duration of illness  (Forbes et al., 2009). Working memory deficits in CHR-
P populations also have been repeatedly measured (Gisselgård et al., 2018; Thermenos et al., 
2016), and have been linked to longer symptom persistence (Broome et al., 2012).  
1.4.3 Verbal fluency  
Verbal fluency is the cognitive function that facilitates information retrieval from memory 
(Patterson, 2011). Verbal fluency needs executive control over cognitive processes of selective 
attention and inhibition, self-monitoring and internal response generation, and is essential for 
communication and social functioning. Verbal fluency is measured by testing semantic and 
phonemic fluency (Shao et al., 2014). Individuals with schizophrenia show deficits in both areas 
of verbal fluency, though the deficit compared to controls is more significant in semantic fluency 
measures (Henry & Crawford, 2005). Evidence of these deficits in verbal fluency remain, even 
when severity of negative symptoms and formal thought disorder are accounted for, though they 
are strong moderators (Galaverna et al., 2016). In CHR-P samples, deficits in verbal fluency are 
found in both semantic and phonemic measures (Hauser et al., 2017). More severe verbal fluency 
deficits have been positively associated with increased risk of transitioning, while lower 
cognitive impairments in domains of verbal fluency is positively associated with remission rates 
in CHR-P (Lee et al., 2014; Sabb et al., 2010).  
1.4.4 Executive function  
Executive function is a broad umbrella term for cognitive processes which operationalize and 
optimize other cognitive processes (Najdowski et al., 2014). Executive functions include 
inhibition, selective attention, cognitive inhibition, working memory, cognitive flexibility, 
adaptability and planning, though the exact definition has little consensus (Diamond, 2013). 
Executive functions are thought to be central to many cognitive processes, in particular to 
problem solving. Executive function deficits are common in those with schizophrenia and FEP 
(Fioravanti et al., 2005). There is evidence that executive functioning deficits are associated with 
deficits in social functioning, and possibly also with symptom severity (Mazurek & Mosiołek, 
2018; A. E. Simon et al., 2003). CHR-P individuals also experience deficits in executive 
function, and it is hypothesized that these deficits start significantly before onset of psychosis 
(Bora & Murray, 2014).  
1.4.5 Motor function 
Motor function describes processes necessary for fine and gross motor movement, muscle 
coordination, muscle strength and balance (Schäppi et al., 2018).  Initial research in 
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schizophrenia identified motor dysfunction as a symptom of anti-psychotic medication (e.g. 
clozapine) (Wang et al., 2019). However, research in drug naïve FEP and CHR-P populations 
showed motor dysfunction in fine motor and neurological soft sign measures(Gschwandtner et 
al., 2006). In schizophrenia, individuals showed deficits in motor coordination such as 
sequencing, sensory integration, motor coordination (neurological soft signs), signs of rigor and 
tremors (parkinsonism), and showed signs of abnormal involuntary movements (dyskinesia) 
(Schäppi et al., 2018). Even when antipsychotic medication is accounted for as a co-variate, 
these findings remain consistent (Wang et al., 2019). Motor dysfunction has been linked to 
symptom severity in CHR-P, FEP and schizophrenia populations, and in CHR-P is associated 
with an increased risk for transition (Callaway et al., 2014; Gebhardt et al., 2008; Wang et al., 
2019).  
1.4.6 Social cognition  
Social cognition describes the mental processes through which people interpret and respond to 
others (Green et al., 2015). Individuals with schizophrenia show difficulties in identifying and 
understanding facial emotions (Kohler et al., 2010). These impairments are not found in 
assessment of non-affective face perception e.g. the age or sex of the face, suggesting it is 
specifically affect facial recognition that individuals with schizophrenia show deficits in (Darke 
et al., 2013). Deficits in this form of social cognition are associated with longer hospitalizations 
and longer time before seeking treatment (Kohler et al., 2010). 
Emotion experiences and emotion regulation have been found to be diminished in individuals 
with schizophrenia (Taylor et al., 2012). Emotion experiences describes immediate responses to 
unpleasant and pleasant stimuli. Emotion regulation describes the two cognitive processes of 
emotion generation and emotion regulation (Gross, 2013). Findings in schizophrenia research 
shows there is increased negative response to neutral and pleasant experiences in those with 
schizophrenia (Horan et al., 2012). This deficit has also been found in CHR-P groups, and is 
associated with increased risk of transition (Corcoran et al., 2015) 
1.4.7 Neuroimaging studies of cognitive deficits  
Measures indicating cognitive differences in those with schizophrenia have also been found in 
neuroimaging studies. Magnetic Resonance Imaging (MRI) creates detailed anatomical images 
of  the human brain through nuclear magnetic resonance (Yan et al., 2007). Meta-analysis of 
MRI studies on individuals with schizophrenia show that decreases in whole brain volume, in 
particular grey matter (Vita et al., 2012). These studies also show that this reduction continues 
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over time. These changes have also been noted to coincide with onset of psychosis (Chung & 
Cannon, 2015; Jung et al., 2012).  
 
Functional Magnetic Resonance Imaging (fMRI) is an imaging method which measures regional 
changes in the brain’s metabolism by measuring blood flow, assuming that increased blood flow 
is a result of increased neural activation (Glover, 2011). This is measured either from local 
cerebral blood flow, or from changes in blood oxygenation concentration (more commonly 
called blood oxygen level dependent(BOLD)) fMRI. Neural activation can be induced responses 
to cognitive tasks, or resting state changes in the brain. These allow measurement of neural 
activation of specific regions of the brain, and by comparing between groups, identify irregular 
activation patterns. Studies and meta-analyses of fMRI studies have consistently shown that 
schizophrenia is associated with aberrant fMRI-activity. In response to cognitive tasks 
individuals with schizophrenia show delayed temporal processing speeds, crucial for executive 
functioning, working memory and other essential cognitive processes (Alústiza et al., 2016). 
Meta-analysis of resting state studies also noted a significant hypoconnectiveness was observed 
in sensory networks, the auditory network (left insula, right superior temporal cortex), and 
somatomotor network (right precentral gyrus) (Li et al., 2019). This review also noted 
hypoconnectiveness in the prefrontal cortex (right medial prefrontal cortex, left, precuneus and 
anterior cingulate cortices), which is involved in decision making, executive function and 
working memory (Euston et al., 2012).  
Magnetoencephalography (MEG) has enabled research to expand on the cognitive deficits in 
those with schizophrenia, by allowing measurement of near instantaneous responses of neural 
activity. MEG measures magnetic fields produced by the electric currents from the dendrites of 
the neurons during synaptic transmission. MEG also allows for a more precise localisation of 
activation and measurement of oscillatory neural activity in higher frequency ranges (e.g. alpha, 
beta, gamma) (Hinkley et al., 2010). This specificity in MEG has shown that there are lateralised 
auditory sensory deficits in those with schizophrenia (Thoma et al., 2003). Individuals with 
schizophrenia have shown deficits in sensory gating (Chen et al., 2018). Sensory gating is a 
cognitive mechanism to filter relevant from irrelevant information from sensory domains, 
deficits in this is associated with experiences of sensory overload, attentional difficulties and 
working memory difficulties (Chen et al., 2018). Other MEG studies have also been able to show 
timing deficits during facial processing (Rockstroh et al., 2006). In resting state measures, 
19 
 
individuals with schizophrenia showed stronger delta and theta power, but a reduction in alpha 
power compared to controls (Cañive et al., 1998).  
1.5 Pathophysiological hypotheses for schizophrenia 
Explanations for the mechanisms which underlie schizophrenia is an area that has been of 
significant interest in understanding the causes of schizophrenia (Stępnicki et al., 2018). 
Research in this area has significantly focused on neurochemical alterations as an explanation 
for what causes schizophrenia, and neurodevelopmental aberrations as an explanation for why 
this happens only to some individuals .   
1.5.1 Neurochemical alterations 
Several neurochemical types and cortical pathways have become focuses in trying to explain the 
mechanisms underlying schizophrenia. While there is some evidence for each of the proposed 
theories, the findings remain inconsistent and incomplete (Stępnicki et al., 2018). Recent 
research has aimed to address these by revising theories to create a theory which encompasses 
more of these findings.  
1.5.1.1 Dopamine hypothesis 
An early area of interest was in dopamine. Dopamine in the brain acts as a neurotransmitter, and 
functions by acting on dopaminergic (DAergic) receptors, classified as D1-like receptors (D1 
and D5) and D2-like receptors (D2, D3, D4). D1-like are primarily excitatory and D2-like are 
primarily inhibitory (Hasbi et al., 2011). Dopamine modulates central functions of the central 
nervous system (CNS), this includes reward and motivation, and higher cognitive functions of 
goal representation and working memory (Cools, 2008). Dopamine has three major pathways in 
the CNS: the nigrostriatal pathway, mesolimbic pathway and mesocortical pathway (Ikemoto, 
2010). The nigrostriatal pathway  transmits dopamine from the substantia nigra to the dorsal 
striatum, the mesolimbic pathway transmits from the ventral tegmental area (VTA) to the ventral 
striatum, and the mesolimbic pathway transmits from the VTA to prefrontal cortex (PFC). 
Dopamine became of interest in psychosis research, following the discovery of the antipsychotic 
properties of the medication chlorpromazine (Gründer & Cumming, 2016). Chlorpromazine 
blocks D2 receptors and when administered to psychotic patients, reduced positive symptoms. 
The original dopamine hypothesis was proposed by van Rossum(1966), and said that D2 
receptors were hyperactive in the mesolimbic pathway in schizophrenic individuals, and this 
caused the condition. This explanation did account for the positive symptoms of schizophrenia, 
but the original hypothesis did not offer explanations of the relationship to continued negative 
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symptoms and cognitive deficits in those who took these early anti-psychotic medications 
(Howes et al., 2015). Further limitations of the theory became clearer with the introduction of 
in-vivo studies, which showed that the early antipsychotic medications were not exclusively 
acting as D2 blocks (Farde et al., 1992), and in fact second generation anti-psychotics with the 
lowest level D2 occupancy were among the most effective. 
A revised dopamine hypothesis was proposed by Davis, Kahn, Ko, and Davidson(1991), they 
focused on expanding the theory by studying the effects of other dopamine receptors, and the 
dopaminergic pathways. The revised hypothesis proposed that in addition to hyperactive 
dopamine D2 receptors in the mesolimbic pathways, there are hypofunctionality of dopamine 
D1 receptors in the mesocortical pathway. It also proposed that this created a disrupted feedback 
loop, where those with schizophrenia have reduced activity in the mesocortical area from the D1 
receptors, which leads to disinhibition and overactivity in the mesolimbic pathway. This was an 
advance from the previous theory, and accounted for some of the observed results from in-vivo 
studies, however it too lacked a specificity, and the theory gave no clear framework as to how 
these conditions interacted to produce the symptoms of schizophrenia (Stępnicki et al., 2018). 
In addition, this version identified that certain dopamine receptors behaved differently for those 
with schizophrenia, but lacked an aetiological explanation for it.  
1.5.1.2 Glutamate hypothesis 
Glutamate is the main excitatory neurotransmitter in the CNS. Glutamatergic pathways link the 
cortex, limbic system, and thalamus, and make up 60-80% of the brains metabolic activity 
(Rothman et al., 2003). Glutamate receptors fall into two groups, ionotropic and metabotropic. 
This distinction marks how neurotransmitter signals when reaching the synaptic membrane bind 
with the receptor (Pankevich et al., 2011). Ionotropic receptors are fast acting and can produce 
large changes in current flow. One of the main glutamate ionotropic receptors is the N-methyl-
D-aspartate (NMDA) receptor. NMDA receptors are thought to be central to learning and 
memory, and have been shown to be vital to neuroplasticity and recovery (Barco et al., 2006). 
Glutamate receptors has also been shown to regulate development and neurotoxicity (Howes et 
al., 2015).  
The NMDA-R hypothesis of schizophrenia was developed following observations that NMDA 
receptors antagonists such as ketamine, dizocilpine and phencyclidine, induced psychotic like 
symptoms when administered to healthy participants (Stępnicki et al., 2018). The original 
glutamate hypothesis focused on a global deficit in glutamatergic neurotransmission, but this has 
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been developed to focus on a hypofunction of glutamate signalling in NMDA receptors (Stone 
et al., 2007).  
Some evidence has supported the glutamate hypothesis (Howes et al., 2015); In animal studies, 
giving animals NMDA receptor antagonists resulted in neurotoxic changes in cortical brain 
regions, suggested to be similar to brain volume reductions found in schizophrenia. Post-mortem 
studies have noted disturbances in glutamatergic receptor density in the prefrontal cortex, 
thalamus and temporal lobes, though the findings have been inconsistent (Kapur & Seeman, 
2002).  
1.5.1.3 GABA hypothesis 
Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the CNS 
(Rudolph & Möhler, 2016). GABAergic interneurons play a central role in synchronization of 
oscillations in local networks and connection between different regions of the brain (Rudolph & 
Möhler, 2016). Abnormal synchronization across regions has been shown to be linked to 
cognitive deficits in attention, working memory and perception (Uhlhaas & Singer, 2006). The 
two main receptors for GABA are ionotropic (GABAA receptor) and metabotropic 
(GABAB  receptor). GABAA receptor has been a focus of research into GABAergic interneurons 
because of its widespread presence in the CNS, and because multiple receptor modulators 
(barbiturates, benzodiazepines, and nonbenzodiazepines) bind at GABAA receptors, allowing for 
in-vivo studies to be more easily conducted (Wassef et al., 2003). The GABA hypothesis 
proposes that disturbances in GABA signaling in the cerebral cortex causes an imbalance 
between the excitation and inhibition, which leads to the cognitive deficits and symptoms of 
schizophrenia (Xu & Wong, 2018).  
Post-mortem studies measuring GABAergic interneurons focused on GABA-synthesising 
enzymes in the PFC. There is consistent evidence to show that GAD67 (a GABA-synthesising 
enzyme) mRNA and protein shows reductions  (Egerton et al., 2017; Tanaka, 2008). Given 
GAD67 is responsible for 90% of GABA production, this is thought to show strong evidence of 
a GABA deficit in the PFC. Animal studies have found injecting  GABAA  antagonist picrotoxin 
into rats create similar inhibition deficits as those with schizophrenia (Wassef et al., 2003). 
However, this activation from picrotoxin has also been linked to dopamine activation, and so if 
these animal studies can be assumed to measure only GABA dysregulation remains unclear. In-
vivo studies also offer mixed results, some studies show GABAA reductions (Frankle et al., 
2015), but meta-analysis show that these findings are inconsistent (Egerton et al., 2017). Clinical 
studies show that administration GABA agonists showed a reduction in schizophrenia 
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symptoms, but like animal studies, because of the interaction of dopamine in these GABA 
agonists, it cannot uniquely identify GABAergic interneurons role in schizophrenia.  
1.5.1.4 Revised hypothesis of GABA-glutamate pathways  
More recent pathophysiological hypotheses have focused on the relationship between glutamate 
and GABA pathways in schizophrenia. It is proposed that there is hypofunction in the glutamate 
NMDA receptors which are located at GABA interneurons, and that this imbalance trigger the 
generation of excessive mesolimbic dopamine activity (Schwartz et al., 2012). In this revised 
theory, glutamatergic and GABAergic dysregulation are the primary mechanism in 
schizophrenia, and  dopaminergic dysregulation is a secondary consequence of this 
dysregulation. This imbalance between glutamate receptors and NMDA interneurons is thought 
to diminish the control of the PFC in schizophrenia (Balu, 2016).    
This theory offers evidence to explain studies which reported findings of dopamine and NMDA 
activation e.g. studies measuring antipsychotics using dopamine antagonists have identified the 
activation of NMDA receptors (Abekawa et al., 2006) This finding showed dopamine-glutamate 
interactions occur intersynaptically and intraneuronally, supporting the linked role (Stępnicki et 
al., 2018).    
In genetic studies, studies using rodents have shown that rodents which are bred to have 
hypofunctioning in the NMDA receptors show decreased inhibition to auditory and visual 
responses, increased social withdrawal, and decreased self-supportive behaviours compared to 
controls (Halene et al., 2009; Nakazawa et al., 2012). These changes mirror the decreased 
inhibition response and negative symptoms associated with schizophrenia. Mice with this 
genetic alteration also show a decrease in neural synchrony, which suggests a hyperactivation of 
the GABAgeric interneurons (Belforte et al., 2010). The evidence supports the potential for this 
relationship, but further research is needed in human studies and animal studies in larger 
mammals and primates.  
1.5.2 Neurodevelopmental Theories of Schizophrenia 
Research into neurodevelopmental aberrations in schizophrenia has traditionally focused on the 
neurodevelopmental hypothesis of schizophrenia. The neurodevelopmental hypothesis proposes 
that events during gestation and early life are the cause of schizophrenia (McGrath et al., 2003). 
Initially proposed by Weinberger (1987) this theory has been criticised for its unclear 
mechanisms on the precise roles between genetics and early life environmental experiences 
(McGrath et al., 2003). However, there is evidence for the role of genetic, prenatal and perinatal 
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risk factors that have been shown to have an effect on later onset psychosis (Jablensky, McNeil, 
& Morgan, 2017), and studies into the interactions between genetics and early environment have 
also shown a relationship to schizophrenia in later life (Misiak et al., 2018).   
1.5.2.1 Genetic risk factors 
Heritability rates for schizophrenia are  estimated to be as high as 64 - 80% in twin studies  
(Hilker et al., 2018; Lichtenstein et al., 2009). Heritability rates are also higher in first degree 
relatives, and even in second degree relatives (Chou et al., 2017). 
Identifying the precise genes conferring risk for schizophrenia has proven to be a significant 
challenge, however. This is because risk genes rarely involve a single gene, but rather a large 
number of genes with small individual effects. To address this question, genome wide 
association studies (GWAS) were initiated (Corvin et al., 2010) that offered an opportunity to 
consider single nucleotide polymorphisms (SNPs)  across large population samples. SNPs are 
common variants of individual nucleotide sequences that are frequently observed in the 
population (>1%; Thapar & Cooper, 2013). In a study of >35000 subjects considering ~9.5 
million SNP variants, they were able to identify 128 independent associations across 108 defined 
loci (Ripke et al., 2014). These included dopamine D2 receptors and glutamate receptors (Pers 
et al., 2016).  
Copy number variation (CNV) describe duplications or deletion in specific regions of an 
individual’s  deoxyribonucleic acid (DNA), and are rare sequence variations (<1%; Thapar & 
Cooper, 2013). These variants can be inherited or can occur as de novo mutations. Building from 
the research of the GWAS study, the Psychiatric Genomics Consortium established a database 
of 41,321 participants to examine the role of specific CNVs in schizophrenia (Marshall et al., 
2017). CNV deletions of locus’ in 22q11.21, 2p16.3 (NRXN1), 15q13.3, 3q29, 16p11.2 distal, 
and 15q11.2 were all associated with schizophrenia, with an odds ratio(OR) between 1.8 – 67.7. 
CNV duplication of 16p11.2 proximal, 7q11.23 and 22q11.21 were associated with 
schizophrenia, with an OR of 0.15 – 16.1. Two CNVs of either duplication or deletion showed 
an increased risk for developing schizophrenia, in the 1q21.1 and 7p36.3 loci, with an OR of 3.8 
and 3.5 respectively. These show significantly higher ORs than SNPS, which are generally <1.5 
(Doherty et al., 2012). The high ORs could in part be due to the need for a relatively significant 
level to be present to be identified, as current measures of CNV lag behind GWAS study 
techniques, suggesting there might be other less frequent CNVs which also play a significant 
role in the development of schizophrenia (Avramopoulos, 2018).  
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1.5.2.2 Prenatal risk factors  
In addition to genetic inheritance, perinatal factors can affect the risks of developing 
schizophrenia. Paternal age shows a non-linear relationship, but suggests that paternal age can 
be a risk factor (Miller et al., 2011). The review found a very small effect size for fathers < 25 
years, a small effect size for fathers ≥ 35 years, and a small to medium effect size for fathers ≥ 
50 years old, when compared to fathers between ages of 25 – 29 years old. Maternal age does 
not show a relationship with increased risk of developing schizophrenia. Maternal illness and 
foetal exposure to diseases including herpes, rubella, and certain microbial agents have shown 
mixed effect sizes, but appear to indicate foetal exposure to these diseases can increase likelihood 
of developing schizophrenia  (Meli et al., 2012; Niebuhr et al., 2008; Yolken & Torrey, 2008). 
There is also some limited evidence for famine and maternal nutrition (Meli et al., 2012). 
Maternal deficits in certain vitamins have yielded strong associations. Mothers with iron 
deficiencies during pregnancy were associated with a four-fold increased risk for schizophrenia 
in the child (Brown et al., 2007). 
Environmental factors during gestation also appear to show an increased risk factor for 
developing schizophrenia. Winter/spring seasons of birth has been shown to have a small but 
significant positive correlation, OR 1.07, with a population attributable risk of 3.3% (Davies et 
al., 2003). Being born in an urban environment, compared to a rural setting, has also been shown 
to have a significant risk factor, with a population attributable risk of 11.73% (Sørensen et al., 
2014).  
1.5.2.3 Perinatal risk factors  
Complications during pregnancy and birth have been associated with increased risk of 
developing schizophrenia. Cannon, Jones, and Murray(2002) showed that complications in 
pregnancy, such as bleeding, diabetes, preeclampsia and certain blood issues (rhesus factors),  
were associated with OR of 1.69 – 7.75.  
1.5.2.4 Childhood risk factors  
The migrant status of an individual has shown to increase the risk of later developing 
schizophrenia for both first and second generation immigrants (2.3 – 2.7 incidence rates ratio 
(IRRs) and  2.1 – 4.5 IRRs respectively) (Bourque et al., 2011; Cantor-Graae & Selten, 2005). 
Both also observed increased IRRs in non-white populations, and Cantor-Graae and Selten 
(2005) noted an increased IRRs in immigrants in low/middle income countries, compared to 
high income countries (3.3 compared to 2.3 IRRs).   
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Abuse during childhood has been linked to schizophrenia incidence (Gallagher III & Jones, 
2013; Seidenfaden et al., 2017) and there is evidence to suggest that the prevalence of certain 
types of childhood abuse are higher in schizophrenia populations (childhood sexual abuse, 26%, 
childhood physical abuse, 39% and childhood emotional abuse, 34%) (Bonoldi et al., 2013). 
Abuse during childhood has been calculated to have an OR of between 1.7 to 15, though several 
other variables including gender, depression, post-traumatic stress disorder, and cannabis use 
moderated these effects (Sideli et al., 2012).  
Drug abuse, in particular cannabis, has been linked to increased risk for schizophrenia. Moore 
and colleagues (2007) showed that any use of cannabis was associated with an OR 1.41 for 
psychotic symptoms and with OR of 1.82 for schizophrenia. Experiences of psychotic 
symptoms, but not schizophrenia, increased significantly when studies focused on frequent users 
(OR 2.09 for psychotic symptoms, 1.82 for schizophrenia).  
1.5.2.5 Limitations of the neurodevelopmental hypothesis of schizophrenia  
The neurodevelopmental theory suggests that there is a relationship between genetics, early life 
experiences and later schizophrenia onset. However, it faces two significant limitations. First, 
there is a significant amount of evidence which shows that FEP individuals experience 
significant changes in global grey matter volume, and synapses connections (Cahn et al., 2009; 
Cahn et al., 2002; Stephan et al., 2006). If the neurodevelopmental disorder theory is correct, 
this significant change during onset should not occur, because the alterations should have been 
present since early infancy. This has resulted in some studies classifying schizophrenia as a 
neurodegenerative disorder (McGrath et al., 2003). Secondly, the neurodevelopmental 
hypothesis does not explain the evidence of environmental factors present in childhood and 
adolescence, which can increase an individual’s risk of developing schizophrenia.  
1.5.3 Alternative theories of neurodevelopmental aberrations  
The hypothesis of neurodegeneration attempts to answer the evidence of the significant 
neurological changes during FEP and throughout the course of illness with schizophrenia. The 
hypothesis proposes that schizophrenia can be characterised as a chronic and progressive 
disorder of the nervous system, resulting in biochemical changes that lead to different clinical 
syndromes (Hardy & Gwinn-Hardy, 1998). In addition to addressing the significant changes 
observed in neuroimaging studies, this theory incorporates evidence of neurochemical 
alterations in supporting the hypothesis. Researchers also draw on evidence of the increased risk 
of relapse following treatment cessation and the mixed evidence for long term efficacy of 
medication as proof of the progressive neurodegeneration (Harrow & Jobe, 2013). This 
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hypothesis, while addressing issues of the neurodevelopmental theory, does face significant 
limitations. The neurodegenerative theory does not address the genetic and environmental 
factors that are shown to be predictive in later onset. In addition, recovery rates in schizophrenia 
are variable, and most evidence for this theory is based only on those classified as having chronic 
schizophrenia (Emsley et al., 2013; Pino et al., 2014).  
The second hit model of schizophrenia has been proposed as an updated version to the 
neurodevelopmental model (McGrath et al., 2003). This theory proposes that early life 
experiences and genetics create alterations in the cerebral cortex. Later risk factors such as 
excessive synaptic pruning, or drug/alcohol abuse in adolescence and early adulthood, then act 
as a second ‘hit’. The second hit can occur any time, though some versions of this theory 
proposed later onset of the second hit to result in lesser effects (Pantelis et al., 2003). This theory 
improves upon the original neurodevelopmental theory by incorporating the later risk factors 
and addresses the significant neurobiological changes measured before and during onset of 
psychosis. More recent research using this model proposes that rather than a binary model, a 
multi-hit threshold model where different environmental and genetic hits at key 
neurodevelopmental milestones offers a better understanding of the complex interactions leading 
to schizophrenia (Davis et al., 2016).  
1.6 Treatment of schizophrenia 
 Treatment of schizophrenia has focused on three key areas; initiation of treatment, medical 
intervention and therapeutic intervention. 
1.6.1 Duration of untreated psychosis  
Initiation of treatment became of interest in schizophrenia research, following evidence that 
individuals who experience longer delays between onset of the psychotic experience and 
appropriate intervention reported poorer outcomes (Marshall et al., 2005). This is referred to as 
the duration of untreated psychosis (DUP).  
Longer DUP has shown to have consistent significant negative functional impacts, with multiple 
reviews showing that those with long DUP experience negative clinical outcomes (Boonstra et 
al., 2012; Marshall et al., 2005; Perkins et al., 2005). Marshall and colleagues (2005) showed 
that individuals who had a long DUP were associated with worse functional outcomes (quality 
of life, overall functioning, social functioning, depression/anxiety) and worse symptomatic 
outcomes (positive symptoms, negative symptoms, disorganised symptoms) at baseline and 
during follow up. Those with long DUP were also shown to have a much lower rate of remission 
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and global functioning long term (Penttilä et al., 2014). Conversely, more recent studies have 
shown that reducing DUP can increase an individual’s response to treatment (Murru & 
Carpiniello, 2018). Some evidence shows that longer DUP has been associated with deficits in 
some cognitive domains, including visual memory, working memory, and verbal memory 
(Amminger et al., 2002; Chang et al., 2013), though these findings have not been replicated in 
other studies (Rapp et al., 2013).  
While DUP has shown as a good predictor of outcomes, it explains a relatively small percentage 
of the overall variance (Penttilä et al., 2014). Emerging literature also suggests that these findings 
may be as a result of lead-time bias, and that DUP better reflects stage of illness, not trajectory 
(Jonas et al., 2020). Additional limitations of DUP research have been identified by Register-
Brown and Hong (2014). The authors noted that across the 132 studies, there was no standardised 
measure to estimate DUP. The most common method to collect data on DUP was using clinical 
interviews, though only 8% reported an inter-rater reliability (IRR). A second issue was that the 
definition for DUP varied between studies e.g. first psychiatric hospitalization, first 
antipsychotic treatment, first treatment of any form. The analysis found that despite this 
limitation DUP showed a consistent but small effect size (0.2 – 0.3) as a clinical measure of 
functional and symptomatic outcome, as well as remission rate. 
1.6.2 Pharmacological interventions in schizophrenia  
First generation antipsychotics, such as  chlorpromazine and haloperidol,  began to be used in 
the 1950’s (Stępnicki et al., 2018). These drugs were effective in reducing positive symptoms 
by acting as dopamine antagonists targeting D2 receptors, though this reduction in positive 
symptoms came with severe side effects (Peluso et al., 2012). First generation antipsychotics 
produced symptoms of psychomotor slowing, affective flattening and emotional quieting. This 
occurs because the medications act as antagonist to D2 receptors throughout the CNS, not just 
the mesolimbic pathway (Li et al., 2016). This leads to the unwanted motor effects, and this 
effect in the prefrontal cortex is thought to exacerbate the negative symptoms of schizophrenia.  
The severity of these symptoms increased risk of nonadherence, relapse and hospitalization 
(Kishimoto et al., 2013).  
Second generation antipsychotics, such as clozapine, olanzapine and risperidone, were thought 
to reduce side effects by reducing reliance on dopamine antagonists (Li et al., 2016). Second 
generation antipsychotics (atypical antipsychotics), target both dopamine (D2 receptors), and 
serotonin (5-HT2A and 5-HT1A receptors) (Stępnicki et al., 2018). These medications show 
similar levels of efficacy in reducing positive symptoms, though evidence of reducing negative 
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and cognitive symptoms has proven inconclusive (Conley & Kelly, 2007; Davies et al., 2007). 
One second generation antipsychotic, clozapine, has been shown to be more effective than first 
generation antipsychotics in treating treatment-resistant schizophrenia (Lieberman et al., 2005). 
Second generation antipsychotics showed reduced neurological symptoms, but have significant 
metabolic side effects, including rapid weight gain, insulin resistance and elevated blood 
pressure (Devlin & Panagiotopoulos, 2015). These symptoms create additional health risks and 
also have shown to decrease rates of adherence (Kishimoto et al., 2013).  
Newer atypical antipsychotics, such as aripiprazole, brexpiprazole and cariprazine, are partial 
D2 receptor agonists (Stępnicki et al., 2018). This is thought to act as a “dopamine stabiliser”; 
acting as an antagonist of the dopamine mesolimbic pathway, but as a functional dopamine 
agonist in the mesocortical pathway (Lieberman, 2004). Efficacy of third generation 
antipsychotics have similar rates to earlier antipsychotic medications in terms of reducing 
positive symptoms, but do not show evidence of reducing negative or affective symptoms (de 
Araújo et al., 2012). The advantage of third generation antipsychotics is significantly less severe 
side effects, though motor disorders  such as akathisia, and metabolic side effects of weight gain, 
insomnia and nausea, are still present (Mailman & Murthy, 2010).  
There remains little evidence that these medications are able to improve negative and cognitive 
symptoms, and as much of  30% of patients continue to experience treatment-resistant 
schizophrenia (Vita et al., 2019). Many patients also need to rely on long term use of 
antipsychotics, with relapse rates following discontinuation being between 62 – 91%, regardless 
of type or length of treatment (Emsley et al., 2013).  
1.6.3 Psychological interventions in schizophrenia  
1.6.3.1 Cognitive Behavioural Therapy 
Cognitive behavioural therapy (CBT) is one of the most common interventions used in 
schizophrenia (Bighelli et al., 2018). CBT focuses on challenging negative patterns of thought 
about the world and self (Rector & Cassin, 2010). In schizophrenia, this has been adapted to 
focus on positive symptoms (Ades et al., 2009). In terms of efficacy, results have varied but in 
a large meta-analysis Bighelli and colleagues (2018) found that overall CBT had a modest effect 
in reducing overall symptoms and positive symptoms (13.2%, 24.8% respectively). Techniques 
such as mindfulness have also shown some improvement on negative symptoms, though the 
results are not robust (Khoury et al., 2013).  
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CBT in conjunction with medication has been shown to increase rates of adherence to medication 
usage compared to medication alone (Guo et al., 2010). CBT shows a small but significant 
improvement in functioning levels, however this improvement was lost following treatment 
discontinuation (Laws et al., 2018). This same effect was found by the meta-analysis for distress 
levels, which decreases marginally during CBT administration, but was not maintained during 
the follow-up period. The study also noted no improvement on quality of life measures at any 
point during CBT treatment.  
One area where CBT has been recently applied is in treatment-resistant schizophrenia patients. 
These are individuals with schizophrenia who are unresponsive to multiple types of 
antipsychotic medications, and represent a significant minority of the population  (Lally et al., 
2016). In this group, CBT has been shown to produce significant improvements in positive 
symptoms, negative symptoms and rates of depression during treatment and at follow up (Sensky 
et al., 2000) 
1.6.3.2 Cognitive remediation  
Cognitive remediation aims to improve the cognitive deficits associated with schizophrenia, and 
by extent improve functional outcomes (Ades et al., 2009). These measures focus on  strategies 
to improve cognition through exercises and development of compensatory strategies to reduce 
effects of persistent cognitive impairments.  
A meta-analysis of 26 studies (n = 1,151) showed that cognitive remediation measures can have 
a marked improvement, even after relatively short intervention periods (m = 12.8 weeks) 
(McGurk et al., 2007). The study found small but significant improvements across global 
cognition, attention/vigilance, processing speech, verbal working memory, verbal learning and 
memory, social cognition, reasoning and problem solving,  but found no effect on visual learning 
and memory. With regards to secondary measures, the study noted a strong effect on general 
symptom improvement, and a moderately strong effect on functioning. The effects of cognitive 
remediation on symptom improvement has been of particular interest, and recent studies that 
targeted negative symptoms have noted small to moderate effects (Cella et al., 2017).  
Recent research has begun to examine neural changes following cognitive remediation therapy. 
Matsuda, Makinodan, Morimoto, and Kishimoto (2019) found limited evidence of changes in 
activation patterns in the frontal brain regions, as well as volumetric changes following 
interventions. While these findings are positive, the evidence is still in preliminary stages as only 
12 studies have so far investigated neurobiological correlates of remediation approaches.  
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1.7 Transition rates 
Interventions still show only moderate and inconsistent improvements in those with 
schizophrenia  (Bighelli et al., 2018; de Araújo et al., 2012). This has increased interest in early 
intervention and identifying those who are at increased risk for transition to psychosis (McGorry 
et al., 2006). One group are those with a genetic risk, such as having a first degree relative with 
schizophrenia. A more predictive model has been found when this genetic vulnerability is 
combined with considering sub-threshold symptoms. Studies which have looked at both have 
noted that in first degree relatives, those who report sub-threshold symptoms are at a significantly 
elevated risk for developing psychosis (Hormozpour et al., 2016; Tandon et al., 2012). Even 
independent of a genetic predisposition, individuals who experience sub-threshold symptoms 
are shown to be at a significantly elevated risk for transitioning to psychosis compared to those 
without (Riecher-Rössler & Studerus, 2017).These two groups have been primarily studied; and 
both groups are referred to as being at CHR-P.   
CHR-P samples are generally studied in help-seeking samples, and the criteria to meet the  DSM 
V diagnosis for Attenuated Psychosis Syndrome include behaviour and distress (Fusar-Poli et 
al., 2018). Non-help seeking CHR-P in some research are considered to be experiencing 
psychotic experiences (McGrath et al., 2015). Psychotic experiences are similar to subthreshold 
symptoms, but occur significantly less frequently, with a majority of those who report them 
experiencing between 1 – 5 psychotic experiences during their lifetime (Kelleher & Cannon, 
2011). Recent research in community samples has demonstrated that there are individuals who 
report subthreshold symptoms at a significantly higher severity and frequency, meeting clinical 
definitions for CHR-P (Haining et al., 2019; McDonald et al., 2019; Mills et al., 2017). This has 
increased interest in research on community sample CHR-P, though research in the area is 
currently limited.  
Research into improving predictive variables in CHR-P populations has focused across multiple 
domains including symptoms, environmental risk factors, and functioning. Mason and 
colleagues (2004) reported that unusual thought content, magical ideation, auditory 
hallucinations and negative symptoms of anhedonia and asociality were the most powerful in 
predicting transition, but these findings were not replicated  (Thompson et al., 2011). Other 
studies have reported suspiciousness/paranoia as an additional predictor (Yung, Phillips, Yuen, 
& McGorry, 2004). Research which considered both prodromal APS and cognitive disturbances 
in BS found an increased risk for transition (Ruhrmann et al., 2010; Schultze-Lutter et al., 2012).  
Environmental factors, particularly use of drugs, has been also associated with increased risk for 
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transition in longitudinal studies, in both genetically vulnerable individuals and those who 
experienced sub-threshold symptoms (Cannon et al., 2008). Recent decline in functioning, in 
combination with symptom type or genetic risk has been shown to have predictive power across 
multiple meta-analyses (Fusar-Poli et al., 2013; Thompson et al., 2011). 
There has been a significant decline in the rates of transition across CHR-P groups. A meta-
analysis by Fusar-Poli and colleagues(2012) showed 22% of transitions after one year and 35.8% 
transitioning after 3 years, in contrast to earlier reports suggesting between 40 – 50% (Yung et 
al., 1998). Possible explanations for declining transition rates  were methodological and 
definitional differences between studies . Rates of transition are also decreasing internally in 
longitudinal large scale studies (Yung et al., 2007) disputing the explanation of methodological 
differences for this effect. Some papers have suggested earlier detection may be creating “false 
positives” by identifying symptoms found in the prodrome of other conditions, such as obsessive 
thoughts or high paranoia (Simon et al., 2014). Comorbidity with axis II disorders have also been 
shown to account for declining rates of transition in some samples (Lim et al., 2018).Yung and 
colleagues (2007) similarly focused on earlier detection and intervention as creating a “dilution 
effect” by reducing rates of transition. However, this explanation was not supported and further 
analysis on this data set, with the study failing to find significant evidence for earlier intervention 
having an effect (B. Nelson et al., 2016). Neither were changes in treatment or changes in sample 
characteristics significant in explaining this decline (Hartmann et al., 2016).  
Transition rates declining has not been found to mirror a decline in number of individuals 
reporting sub-threshold symptoms (B. Nelson et al., 2016). This has created more academic 
interest in CHR-P, and increased research into outcomes in this group.  
1.8 Subthreshold symptoms in CHR-P 
Subthreshold psychotic experiences  are divided similar to schizophrenia symptoms into two 
categories; positive and negative symptoms (Yung et al., 2005). In addition, CHR-P 
characterized by self-reported cognitive changes, so-called basic symptoms, which can continue 
in those with schizophrenia (Schultze-Lutter et al., 2016). Nonspecific symptoms are also 
characteristic of the prodromal stage (Fusar-Poli et al., 2013). Shah and colleagues (2017) found 
that subthreshold symptoms are present in the majority (68%) of those who will go on to 
experience FEP, and non-specific symptoms were reported in both those who experienced 
subthreshold symptoms and those who reported no other subthreshold symptoms.  
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There are gender differences in CHR-P populations. Male participants with CHR-P have more 
severe negative symptoms, worse social functioning, report earlier onset of symptoms and longer 
duration of untreated symptoms (Barajas et al., 2015; Rietschel et al., 2015). Age of onset, 
regardless of gender, is also associated with worse functional outcomes (Häfner, 2000; Schultze-
Lutter, Rahman, et al., 2015). 
However, growing research into community samples show there are individuals who are not 
help-seeking, but which meet criteria  
1.8.1 Nonspecific symptoms  
Nonspecific symptoms in CHR-P describe a range a negative functional outcomes, including 
poor school and social functioning, and low psychological measures including anxiety symptoms 
and depressed mood (Lencz et al., 2004). These symptoms commonly precede onset of other 
forms of subthreshold symptoms (Schultze-Lutter, Rahman, et al., 2015). Nonspecific symptoms 
are not considered criteria for CHR-P (Lencz et al., 2004).  
1.8.2 Negative symptoms 
Negative symptoms are present in CHR-P individuals (Lencz et al., 2004) and fall into two 
distinct clusters: 1) diminished expression and 2) amotivation. Diminished expression describes 
experiences of affective flattening and poverty of speech, while amotivation describes symptoms 
of avolition, apathy, asociality and anhedonia. Despite not generally considered as an inclusion 
criteria for CHR-P, growing evidence shows that individuals who experience more severe 
negative symptoms, as well as APS, are more likely to transition than those without (Demjaha 
et al., 2012; Fusar-Poli & Borgwardt, 2007).  
1.8.3 Attenuated psychotic symptoms  
APS manifest like full positive psychotic symptoms, but are present to a lesser degree in 
intensity, frequency and/or duration (Fusar-Poli et al., 2013). In general, there are four clusters 
of APS positive symptoms: 1) unusual thought content (UTC) 2) non-bizarre ideas (NBI) 3) 
perceptual abnormalities (PA) 4) and disorganised speech (DS). UTC describes thoughts and 
beliefs characterised by strange, fantastic, or bizarre ideas, which range from atypical to severely 
distorted or illogical (Sinott et al., 2016).  NBI describes delusions that are possible in real life, 
though they are atypical or improbable (Sinott et al., 2016). PA describe any perceptual 
experiences, which can be in the form of a general wider experience of distortions or illusions 
(e.g. hearing feeling muted), or specific hallucinations (e.g. hearing a voice) (Yung et al., 2005).  
Disorganised speech describes clusters of symptoms to do with how the participant uses 
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languages, either self-reported or objectively measured. Measures of APS differ slightly on 
groupings of these clusters, e.g.  the Comprehensive Assessment of At-Risk Mental State 
(CAARMS) treats NBI as one set of symptoms, while the Structured Interview of Prodromal 
Syndromes (SIPS) splits NBI into two distinct categories of suspiciousness/persecutory ideas 
and grandiosity (Miller et al., 2003; Yung et al., 2005). To be considered to have an APS an 
individual must have a symptom in one of these categories which meets a severity threshold. In 
addition, the symptom must be present with a certain frequency and/or duration i.e. in CAARMS 
the frequency/duration level is at least once a month for more than an hour per occasion, or 3 
times per week less than an hour per occasion. Some individuals experience full psychotic 
symptoms, but for brief periods of time (< 1 week) that rather than continuing into transition, 
remit without treatment (Yung et al., 2005). This CHR-P group meets criteria for brief limited 
intermittent psychotic symptoms (BLIPS).  
1.8.4 Basic symptoms 
BS are self-identified changes in thought processing, perception, language and attention 
(Schultze-Lutter et al., 2016). BS are mostly identified using the Schizophrenia Proneness 
Instrument, Adult/Child & Youth (SPI-A/SPI-CY)  (Schultze-Lutter et al., 2015). This measure 
detects two BS categories; cognitive-perceptive basic symptoms (COPER) and cognitive 
disturbances (COGDIS). These groupings describe partially overlapping symptoms and 
experiences. COPER describes disturbances in thought and perceptual experiences. COGDIS 
describes disturbances in thought, language and some perceptual experiences. CHR-P may meet 
criteria for either or both COPER and COGDIS experiences, and both are determined by meeting 
the symptom criteria, and experiencing it at a reasonably frequent level (several times a month 
or more frequently). To meet COPER criteria, an individual must have first experienced these 
symptoms more than a year ago, while for COGDIS they can have emerged at any time.  
Both sub-types of BS are thought to present before onset of psychosis, and be present during 
psychosis  and in remission (Schultze‐Lutter & Theodoridou, 2017).  Several studies have 
identified BS as a distinct stage, the early at-risk mental state, which is characterised by the onset 
of these self-identified cognitive and perceptual changes. The late at-risk mental state is 
classified by presence of BS as well as APS and/or BLIPS (Bechdolf et al., 2012; Salokangas & 
McGlashan, 2008). Current theories  (Fusar-Poli et al., 2013) assume that BS precede the onset 
of APS during the prodromal stage. It has been proposed that basic symptoms reflect the 
immediate symptomatic expression of the neurobiological processes underlying schizophrenia 
(Schultze-Lutter et al., 2016).  Evidence of the significance of BS in risk of transition show that 
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COGDIS criteria has shown high predictability of transition within 4 years (54.9%; Schultze-
Lutter, Michel, et al., 2015), and measurement of both BS and APS has shown to further increase 
predictability (Schultze-Lutter et al., 2012b). 
In this conception of BS, it is hypothesised that attenuated and overt psychotic symptoms 
develop as a secondary phenomenon, resulting from poor coping strategies of emerging BS and 
associated stressors (Schultze‐Lutter & Theodoridou, 2017; Schultze-Lutter, 2009; Schultze-
Lutter et al., 2016). Currently only one  study has been conducted to measure evidence of this 
relationship. The study was conducted on an FEP sample and found the predicted relationship 
of BS onset prior to APS onset only when level of education was accounted for. When this was 
not factored in, the study found a third of participants reported BS onset before APS (n = 27, 
33.3%), a third reported them starting in the same month (n = 29, 35.8%) and a third reported 
BS onset after APS (n = 25, 30.9%) (Schultze-Lutter et al., 2010). Two explanations were offered 
for this disparity. One explanation for this disparity was the recall bias an individual might 
experience for APS symptoms, compared to BS which are more subjective. A second suggestion 
is that health care and higher education both have a socio-economic component to them. This 
means that in a help-seeking FEP sample, there is likely to be a higher level of wealthy 
individuals, and that this group is also more likely to attend college. The studies which initially 
pioneered the BS concept were also skewed in this manner (Schultze-Lutter et al., 2007a, 2008), 
and the paper suggests that a selection bias may account for why comparisons between groups 
showed different expected outcomes.   A second study examining how non-specific subthreshold 
symptoms, as compared to  the onset of  APS and BS were affected by age of onset, found 
younger people (<18 year old) reporting fewer and shorter unspecified prodromal  symptoms 
(Schultze-Lutter, Rahman, et al., 2015).   
1.9 Cognitive deficits in clinical high risk for psychosis individuals 
A meta-analysis of studies on neurocognitive deficits in CHR-P found evidence that they occur 
in multiple domains, including attention, working memory, processing speed, executive 
function, verbal fluency, visual memory, verbal memory and noting particularly robust 
impairments in symbol coding and visuospatial working memory (Bora et al., 2014). This study 
also considered CHR-P individuals with only a genetic vulnerability, but no APS or BS. In this 
group there was also impairment across all domains compared to controls. Compared to CHR-P 
groups with symptoms, the genetic risk group showed comparable results in other cognitive 
domains. CHR-P Individuals with both a genetic risk and APS symptoms showed more severe 
deficits in verbal memory and sustained attention. Other large reviews found comparable results 
35 
 
across most domains, but failed to find deficits in processing speed (Fusar-Poli et al., 2012).  A 
study measuring cognitive deficits in CHR-P with BS found that the presence of COPER 
symptoms predicted cognitive deficits only in executive control and verbal memory (Frommann 
et al., 2011). It is proposed that this may indicate that BS generally precede neurocognitive 
impairments (Schultze-Lutter et al., 2016). In community samples, CHR-P were found to 
perform significantly worse in executive functioning and motor speed tasks, as well as overall 
diminished cognitive scores (Haining et al., 2019). Fusar-Poli et al., (2012) also noted deficits 
in social cognition, and found that they had larger effect sizes than  other cognition measures. In 
particular deficits in discriminating between neutral and negative emotions have been observed 
(Corcoran et al., 2015). Individuals with worse facial affect was also associated with lower scores 
on spatial working memory and attention, compared to other CHR-P individuals (Yong et al., 
2014).  Difficulty identifying other people’s facial expressions have also found in CHR-P 
compared to control (Piskulic et al., 2016) and are associated with worse functional outcomes 
(Matrunola, 2017) as well as increased risk of transition (Piskulic et al., 2016).   
1.10 Outcome measures in CHR-P individuals 
1.10.1 Remission  
Only 22% of CHR-P individuals transition to psychosis (Fusar-Poli et al., 2012). In addition, a 
substantial number of   participants meeting CHR-P criteria continue to experience sub-threshold 
symptoms over several years. (Beck et al., 2019) found that remission was around 50% at 2 – 3 
year follow up, and this increased to 70% in studies after a 6 – 7.5-year period. While positive 
symptoms tend to remit at around 2 years, mood and anxiety symptoms tended to persevere for 
significantly longer durations (de Wit et al., 2014). There remain insufficient explanations into 
why there are differences in rates of recovery, and what the effect these long periods 
experiencing sub-threshold symptoms have on those who experience them.  
1.10.2 Functional outcomes 
APS and BS are associated with decreased functioning across multiple domains (Ruhrmann et 
al., 2010; Salokangas & McGlashan, 2008). These findings have also been demonstrated in 
community sample CHR-P (Haining et al., 2019). Studies show that individuals who 
experienced APS have significant impairments compared to controls in both role and social 
functioning at three year follow up (Addington, Cornblatt, et al., 2011). Explanations for the link 
between symptoms and functional decline refer to the impact of both negative and positive 
symptoms as significant contributors in functional impairments (Fulford et al., 2013; Salokangas 
& McGlashan, 2008).  
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Prevalence of co-morbidity in CHR-P has also been observed, with a number of studies finding 
a high prevalence of Axis-I diagnosis, particularly anxiety and affective disorders (Michel et al., 
2018). This prevalence was present to approximately the same degree across remitted and non-
remission CHR-P groups (63% and 67% respectively) (Beck et al., 2019).  
1.11 Treatments  
There are currently limited treatments and intervention options available for CHR-P individuals 
and their efficacy in reducing risk of transition and functional impairments have been modest 
(McFarlane et al., 2015). 
1.11.1 Psychological intervention 
Cognitive remediation has so far not  shown significant effects in improving symptoms or 
reducing transition rates in CHR-P populations (Piskulic et al., 2015). CBT has shown to 
improve APS severity in CHR-P groups, but not transition rates (van der Gaag et al., 2012). 
Psychoeducation has shown to have some effects in improving role functioning, but not reducing 
risk of conversion to psychosis (McFarlane et al., 2015).  
1.11.2 Medication  
Second generation antipsychotic medications, such as amisulpride and risperidone, have shown 
effects on improving symptoms and reducing rates of transition (Phillips et al., 2009; Ruhrmann 
et al., 2007). There are concerns regarding unnecessary prescription of these medications, which 
have significant metabolic side effects (Devlin & Panagiotopoulos, 2015), and predicting those 
most at risk for transitioning still only shows an accuracy of 35% (Thompson et al., 2011).   
1.11.3 Non-specific treatments 
Non-specific interventions have grown more common in mental health services, designed to 
reflect the significant overlap in the early development of many disorders  (Mei et al., 2019). 
Non-specific treatments such as nutritional supplements have shown to effect on prognostic 
outcomes at baseline and follow up (Amminger et al., 2015). Non-specific psychological 
interventions such as supportive counselling showed evidences of improvements of symptom 
severity equivalent to equivalent to CBT (Addington, Epstein, et al., 2011). The evidence of 
preventative studies suggests that the effects of these interventions are moderate, but stable 
across multiple studies (Nelson et al., 2020). 
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1.12 Duration of untreated prodromal symptoms  
Duration of untreated prodromal symptoms (DUPrS) describes the onset of prodromal symptom 
until first intervention or until onset of FEP, though the definition of DUPrS varies across studies. 
Evidence shows that there are functional differences in the outcomes of FEPs for those who 
experience prodromal symptoms compared  to those who do not  (Shah et al., 2017). 
Research into DUPrS has focused on two separate groups: 1) studies focused on DUPrS in FEP 
and  transitioned populations, and 2) in CHR-P non-transitioned populations.   
1.12.1 Duration of untreated prodromal symptoms in FEP  
The most common approach to studying DUPrS is to examine FEP populations retrospectively, 
which was employed in 24 studies. However, not all studies provided details on length of 
duration, or measured duration of symptoms while an individual was FEP, which does not 
measure only DUPrS (Powers et al., 2019). There has also been very little standardisation in 
assessing duration (Powers et al., 2019). In more recent studies, there was use of structured 
interview tools, such as the Early Recognition Inventory (ERIraos) (Schultze-Lutter, Rahman, 
et al., 2015), but there was no consistency between papers.  Most papers only considered APS 
(Huber et al., 1980;  Malla et al., 2002; Powers et al., 2019; Rabiner et al., 1986; Shah et al., 
2017) while only one also considered BS (Schultze-Lutter, Rahman, et al., 2015). 
1.12.1.1 Outcomes of DUPrS in FEP samples 
Transition rates 
Rates of APS in FEP populations has been of interest in DUPrS research. One large study from 
the Personal Assessment and Crisis Evaluation (PACE) study measured DUPrS in those who 
converted to psychosis and found that  95% converted within 5 years of onset of symptoms (m 
= 61.02 months) (Powers et al., 2019). Not all studies have found this relationship, one study 
noted that duration of prodromal symptoms was only predictive in conjunction with other 
factors, such as  family history and education (Huber et al., 1980).  
Functional outcomes 
Longer DUPrS is associated with lower general functional scores in FEP individuals (Keshavan 
et al., 2003). This finding remained true even when premorbid adjustment was accounted for, 
and was found at 1 and 2 year follow up. FEP individuals with longer DUPrS for BS also showed 
lower help-seeking behaviours compared to short DUPrS individuals (Schultze-Lutter, Rahman, 
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et al., 2015). This delay in help-seeking increases the length of DUP and can add significantly 
to rates of relapse and low functioning (Norman & Malla, 2001).  
Symptomatic outcomes 
In FEP studies, DUP is associated with lower rates of recovery (Perkins et al., 2005). The 
findings of these papers for the influence of DUPrS in FEP recovery has indicated there may be 
some effect. One paper found that shorter DUPrS was associated with lower levels of negative 
symptoms in FEP, specifically levels of anxiety (Malla et al., 2002).  Relapse rates have also 
been shown to be associated with DUPrS (Rabiner et al., 1986) 
1.12.2 Duration of untreated prodromal symptoms in CHR-P 
Emerging data has highlighted that DUPrS in participants meeting CHR-P may confer a similar 
relationship with clinical and functional outcomes as observed in FEP (Zhang, Xu, Tang, Cui, 
Tang, et al., 2018). The term prodromal is used in this research, which denotes the early stage of 
a condition which progresses (Addington, 2003) . This cannot be assumed for CHR-P as a 
majority will not transition (Shah et al., 2017). However given evidence of the long term negative 
outcomes of experiencing subthreshold symptoms, even in those who do not transaction (Beck 
et al., 2019), research into the effect of longer duration of subthreshold symptoms in this 
population is still a necessary area of research.    
research has ten studies explicitly focused on DUPrS in non-transitioned populations and its 
impacts on outcomes.  All current research has been conducted in clinical CHR-P cohorts. There 
is currently no standardized tool to measures DUPrS. Instead all papers used self-reported data 
obtained from other instruments to establish DUPrS. These include  SIPS, CAARMS and  
ERIraos.  
1.12.2.1 Outcomes of DUPrS in CHR-P samples 
Transition rates 
Findings in CHR-P populations show some mixed evidence that DUPrS may be predictive for 
transition rates. (Zhang, et al., 2018b) examined a clinical population over one year to observe 
differences in conversion, but found no relationship between length of DUPrS and conversion.  
Similarly, Carrión et al., (2016) and Zhang et al.,(2017) noted no relationship between the length 
of DUPrS and conversion, though both observed that the number of sub-threshold symptoms 
positively correlated with conversion rates.  Two findings from the PACE study differed on these 
findings in a CHR-P sample. Yung and colleagues(2004) found that length of DUPrS to be 
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predictive of transition. Nelson et al. (2016) observed individuals with long DUPrS (> 1 year) 
had a significantly higher conversion rate  (56%) compared to those with a shorter DUPrS (< 1 
year; 32 %). In Nelson et al.(2016) individuals who entered treatment with shorter DUPrS also 
showed evidence that they did not reach same transition rate levels as those who entered 
treatment with longer DUPrS. One study measuring BS (Schultze-Lutter et al., 2007) found that  
dividing symptoms by length of DUPrS could increase prediction of risk of transition.  
Functional outcomes  
Four studies considered functional outcomes in CHR-P individuals with longer DUPrS.  
Functional decline was broadly shown to be linked to longer DUPrS. Zhang and 
colleagues(2018a) found a statistically significant impact of DUPrS on negative functional 
outcomes, but not functional recovery. Carrión et al., (2016) found that negative symptoms were 
associated with poorer social functioning, but positive symptoms were not associated with poor 
role or social functioning. Fusar-Poli et al. (2009) found that individuals experiencing BS 
showed a decline in GAF over a year follow up.  Zhang, et al., (2018b) found that those with 
longer DUPrS experienced lower GAF scores overall than shorter DUPrS groups. Zhang et 
al.(2017;2018b) found this difference was more significant when the sample was divided into 
short and long duration. Individuals in the longer DUPrS  group had significantly worse 
outcomes than short DUPrS. In measuring number of symptoms, longer DUPrS in APS was also 
associated with statistically more negative symptoms 
Symptomatic outcomes 
Only one paper in CHR-P research by tracked symptomatic changes in APS in relation to DUPrS 
(Zhang et al., 2018a). The study measured a cohort of CHR-P individuals over a two-year follow-
up period and remission of APS was assessed. The paper did not find a statistically significant 
impact of DUPrS on symptomatic outcome. 
1.13 Aims of the thesis  
There is growing evidence to show that there is a significant population of CHR-P, who 
experience clinically defined CHR-P subthreshold symptoms of APS and BS (Schultze-Lutter, 
Michel, et al., 2015), but who do not seek early interventions (Mills et al., 2017). Online 
screening methods have allowed research to expand samples beyond help seeking groups, and 
recent evidence has shown the efficacy of these programs in detection of CHR-P from 
community samples (McDonald et al., 2019). In light of this, there is a need to expand research 
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in this area, and compare results of this group, to the more widely studied CHR-P help seeking 
group.  
Using online screening methods to identify CHR-P individuals from a non-help seeking 
community sample, this thesis aims to address the identified gaps in the current literature on 
DUPrS. Three central questions are examined in the course of this text; 
1. Does the assumed relationship of BS onset preceding APS onset occur in a CHR-P 
sample?  
The current literature on duration of sub-threshold symptoms in CHR-P is still in preliminary 
stages, with significant gaps in the literature. One significant area is that to date only one study 
has measured the duration of BS compared to APS, and only in an FEP sample (Schultze-Lutter 
et al., 2010).  The assumption that BS onset precede APS onset is central to the hypothesis that 
BS are the immediate symptomatic expression of the neurobiological processes, and that APS 
symptoms are a secondary consequence of poor coping to BS and associated stressors (Schultze-
Lutter et al., 2016).  This hypothesis is influential and commonly used in many areas of CHR-P 
research (Bechdolf et al., 2012;Fusar-Poli et al., 2013; Salokangas & McGlashan, 2008), but has 
not been validated in a CHR-P sample.  
2. Is there an effect of duration of APS or BS, on functioning, and does this differ in those 
with  longer or shorter duration? 
Measures of the effect of DUPrS on functional outcomes have only begun to be explored, and 
only in clinical samples (Carrión et al., 2016; Fusar-Poli et al., 2009; Zhang et al., 2017; 2018b). 
This research  aims to replicate these findings in a community sample, and explore the effect of 
BS duration on functioning measures.  
3. Is there effect of duration of APS or BS, on cognition? 
Other deficits found in CHR-P samples and the effect of duration of sub-threshold symptoms 
have been neglected e.g. only one study has measured the effect of DUPrS on  cognition, and it 
was not reported in the main findings (Chon et al., 2015). This paper aims to address this deficit 
by examining the effect of APS and BS duration on multiple measures of cognition.  
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2 Methods 
2.1 YouR study design  
The data for this project was collected as part of the Youth Mental Health Risk and Resilience 
(YouR) study (Uhlhaas et al., 2017). This is a longitudinal, multisite project investigating the 
psychological and neurobiological predictors of emerging psychosis. This study is funded by the 
Medical Research Council (MRC). The YouR-study was approved by NHS Research Ethical 
Committee Glasgow and Greater Clyde.  
The YouR study collects multiple variables on CHR-P at baseline, including clinical measures, 
functioning and cognition measures, and neuroimaging measures including fMRI and MEG. 
Recruitment was continuously conducted throughout the year, once a participant met recruitment 
criteria they were immediately invited to a 1st baseline assessment to assess CHR-P state. 
Participants who met CHR-P criteria were then invited to 2nd baseline assessment at earliest 
convenient, generally between 2 – 3 weeks following initial screening. Subsequent baseline 
assessments follow this design and participant generally complete all four baseline assessments 
at 6 – 9 weeks from first assessment. A healthy control group was also collected who completed 
these baseline assessments.  Follow up data using the same measures were collected every six 
months on the CHR-P group for the following three years, but not the healthy controls. For full 
details see (Uhlhaas et al., 2017).  
The YouR study has been collecting data since 2016, and was still actively recruiting and 
screening CHR-P participants throughout 2018/2019. As part of the YouR research team, and to 
complete a thesis using the data, all researchers, including myself, assisted baseline 
demographic, clinical, functioning and cognitive assessments, neuroimaging procedures and 
completed follow up on participants. The control group was collected in 2016/2017 and does not 
have follow up data, so I did not participate in collecting this data.  
Additional responsibilities throughout my year in the YouR study was to run recruitment, this 
included running an email campaign, acting as NHS liaison, and maintaining the recruitment 
website. My responsibilities also included scheduling initial screenings, baseline assessments 
and follow up assessments.  
Not all measures collected in the YouR study were used in this current research, including fMRI 
and MEG imaging data and follow up data. The protocols of the YouR study used in this research 
are highlighted in Figure 1. 
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Figure 1. Flow chart of YouR study protocol measures used in the current research 
 
2.2 Recruitment and participants 
The CHR-P group was recruited from the general population and through clinical referrals from 
NHS-patient services. 92% were recruited from the general population, using flyers, transport 
advertisements and an email campaign. An email campaign was conducted across incoming first 
year students to colleges and universities in Edinburgh and Glasgow, and invited individuals to 
participate in an initial online pre-screening questionnaire (www.your-study.org.uk), The 
majority of recruited participants came from third level institutions (n = 129, 84.86%).  
Informed consent was obtained online. Participants then completed the 16 item version of the 
prodromal questionnaire (PQ-16; Ising et al., 2012) as well as a 9 item-scale for the assessment 
of perceptual-cognitive anomalies (PCA). Participants were invited for clinical assessments if 
they endorsed six or more PQ-16 items, or 3 items on the PCA-scale. 
Two inclusion criteria were identified in order for individuals to complete the online survey; 
they must be between 16 – 35 years old, and have normal/corrected to normal vision. Exclusion 
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criteria included having a diagnosed psychotic condition, or having any metal implants. 
Individuals who met criteria from the online survey were contacted for a first in person 
assessment. A portion of those who failed to meet any criteria were also contacted as a control 
group.  
A total of 153 (107 female, 46 male) CHR-P individuals screened at baseline were used in this 
study. 135 (97 female, 38 male) of those completed the first three baseline assessments. A control 
group (n = 80, 61 female, 19 male) was collected of which 57 completed first three baseline 
assessments (40 female, 17 male). Most individuals were recruited from the general population, 
with 8 being collected from referral. 
2.3 Demographic information 
Demographic information was initially collected from the participant at baseline. This included 
age, years of education, citizenship, housing situation, specific learning difficulties, and family 
history of illness. Social factors including smoking, drinking and drug use was also recorded. 
Participants were asked about any instances of physical or mental illness in the last twelve 
months. If an incident of mental illness was reported, any diagnosis, medication and treatment 
was recorded. Suicidality and self-harm behaviours current and past were also assessed. 
Individuals who expressed current high suicidal ideation or intent were referred to appropriate 
services and excluded from the study. 
2.4 Assessment of clinical high-risk status 
Individuals who had met the pre-screening criteria were invited for an interview to determine 
CHR-P status. The two measures used were the CAARMS (Yung et al., 2005) and the SPI- A 
(Schultze-Lutter, Addington, et al., 2007). CAARMS was used to assess if a participant met at-
risk mental state (ARMS) criteria, and shows a strong inter-rater reliability (IRR .85) (Yung et 
al., 2005). The positive scale of CAARMS was administered which included the following 
subscales: unusual thought content (UTC), non-bizarre ideas (NBI), perceptual abnormalities 
(PA) and disorganised speech (DS). Each of these are rated on a scale of 0 – 6 for intensity and 
frequency. In addition, the onset of the experience was recorded. Participants were asked to score 
their own distress regarding the experiences described on a scale of 0 (not distressed at all) to 
100 (extremely distressed). A score for severity of positive symptoms was calculated using the 
summed scores of the product of intensity and frequency for each of the four subscales. 
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To meet CHR-P, participants needed to meet the criteria of at least one of the ARMS groups: 
1. Group 1: ARMS Vulnerability Group: A family history of psychosis in a first degree 
relative or identified schizotypal personality disorder in the individual and a 30% drop in 
Global Assessment of Functioning (GAF) score from premorbid level, sustained for a 
month, occurred within past 12 months 
2. Group 2: ARMS Attenuated Psychosis Group: Individuals who experienced 
subthreshold psychotic symptoms which started or worsened in the past 12 months. The 
experiences needed to have a global (intensity) score of ≥ 3 for UTC, NBI, PA and a 
global score of ≥ 4 in DS. In addition, the symptom needed to have a frequency score of 
≥ 3 (frequency score 3 = “Once a month to twice a week, more than one hour per occasion, 
or 3 to 6 times a week - less than one hour per occasion”).  
3. Group 3: ARMS Brief Limited Intermittent Psychosis Syndrome (BLIPS) Group: 
Individuals who experienced a short period (< 1 week) of full psychotic experiences, 
which resolved without treatment. The experience needed to have a global score of 6 for 
UTC, NBI and DS, or a global score of 5-6 for PA. In addition, the symptom needed to 
have a frequency score of  ≥4. 
SPI-A was used to assess if a participant met COGDIS and/or COPER criteria. To meet SPI-A 
criteria, BS symptoms had to be present in the last three months. Symptoms were scored based 
on frequency (0 – 6) over the last three months. A score of moderate (3, several times in a month 
or weekly) to extreme (6, daily but not necessarily continuously) was considered as the symptom 
being present. 
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 Table 1. List of COGDIS and COPER criteria, as identified in the SPI-A measure (Schultze-
Lutter, Addington, et al., 2007) 
COGDIS criteria 
At least two of the following BS: 
COPER criteria 
At least one of the following BS, which 
started over 12 months ago: 
Inability to divide attention (B1) Thought interference (C2) 
Disturbances of expressive speech (C5) Thought blockage (C3) 
Disturbances of abstract thinking (O3) Disturbance of receptive speech (C4) 
Captivation of attention by details of the 
visual field (O7) 
Thought pressure (D3) 
Thought interference (C2) Unstable ideas of reference (D4) 
Thought blockage (C3) Thought preservation (O1) 
Disturbance of receptive speech (C4) Decreased ability to discriminate between 
ideas/perception and fantasy/true 
memories (O2) 
Thought pressure (D3) Derealization (O8) 
Unstable ideas of reference (D4) Visual perception disturbances (D5, F2-
F3, O4.1-O4.10) 
 Acoustic perception disturbances (F5, 
O5.1-O5.2) 
 
2.5 Assessment of duration of prodromal symptoms 
DUPrS was obtained retroactively from the CAARMS and SPI-A baseline screenings. This had 
previously been reported during interviews but not recorded in the dataset. As part of the current 
research for this thesis a dataset was created which included duration of each symptom reported 
for all CHR-P in the YouR study. Additional information including symptom subtype, age at 
onset of symptom, the life stage of the individual when the symptom onset and if a symptom 
was continuous or remitted were recorded.  
Duration of symptoms was only recorded on items which had been scored as  meeting APS or 
BS criteria. Neither CAARMS or SPI-A have a duration specific question in the measures, but 
both have duration specific requirements. To meet criteria of CAARMS symptoms must have 
started or become worse in the last year. To meet SPI-A COPER criteria, symptoms must have 
onset over 12 months ago. This meant participants were generally asked start dates of reported 
symptoms on CAARMS to gather this criterion, 77.57% of reported CAARMS items had a 
recorded duration, and 68.67% of SPI-A items. Only participants who reported a DUPrS were 
included in the analysis.  
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DUPrS is collected retroactively, which increases the risk of inaccurate recollection and 
reporting from participants. Only reported DUPrS where the participant was able to identify the 
month of onset, the year of onset (treated as January 1st of that year), or the age they were when 
the symptom onset (treated as date of birthday for that year), were included for analysis. 
Symptoms where the onset was not recorded, or the participant was unable to provide a defined 
onset time, were excluded. Duration was determined by the number of months from onset until 
the date of the baseline interview, in line with previous studies (Carrión et al., 2016; Chon et al., 
2015; Nelson et al., 2016; Schultze-Lutter et al., 2010; Zhang et al., 2017; 2018a, b), the DUPrS 
for the present study was recorded in months. 
2.6 Assessment of functioning 
During the first baseline interview, the overall functioning of the participant in the last month 
was assessed using the global assessment of functioning (GAF). The GAF is a scale from 1 – 
100 (1 being significantly inferior dysfunction and 100 being significantly superior functioning). 
This scale is further divided into 10 equal intervals, each with specific criteria over three areas 
of functioning; psychological, social and occupational. Two interviewers score the participants 
responses to questions about how their sleep, appetite, college work, employment, socialising 
with friends and  family and mood have been in the last month. The GAF shows good IRR (0.89); 
(Startup, Jackson, & Bendix, 2002).  
During the second baseline assessment Social and Role scales (GF: social and role; Cornblatt et 
al., 2007) were administered that assess role (occupational) functioning and social functioning 
of CHR-P individuals. The scales are measured separately and exclude psychological 
functioning e.g. subthreshold psychotic symptoms, to provide independent measures on these 
specific areas of functioning, rather than an overall assessment measured in GAF. For the GF 
role scale, participants are asked about their experiences in school/college/work/house work, 
depending on the age and occupation of the participant. Instances of failing exams or demotions 
at work are recorded, and how the participant feels they manage the pressures and demands of 
their occupation. The social scale focuses on friendships, family and romantic relationships, and 
instances of conflict and frequency of communication are recorded.  To score the interviews, the 
two scales have a ten point range from 1 -10 (1 = extreme dysfunction, 10 = superior functioning) 
with each point on the range having defined features of the functioning levels for each point. A 
CHR-P individual would be expected to score between 6 – 8 on both the GF social and role 
scales, and the measures show high IRR (.956; Carrión et al., 2019).  
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2.7 Assessment of cognitive functioning  
During the third baseline visit the Brief Assessment of Cognition in Schizophrenia (BACS; 
Keefe et al., 2004) and subtests from the Penn Computerized Neurocognitive Battery  (Penn 
CNP; Moore, Reise, Gur, Hakonarson, & Gur, 2015) are administered.  
The BACS assess six areas of neurocognitive functioning: 1) verbal memory, 2) working 
memory, 3) motor function, 4) attention and processing speed, 5) verbal fluency and 6) executive 
control. The BACS shows excellent test-retest reliability (interclass correlation coefficient (ICC) 
= 0.73). A seventh composite total score is calculated following completion of the task, and also 
shows strong test-retest reliability (ICC = 0.90) (Keefe et al., 2004).  
The Penn CNP is a computer administered cognitive test battery (Moore et al., 2015) with high 
test-retest across domains (ICC > 0.6, Roalf et al., 2013). In the YouR study, the Penn 
Continuous Performance task which measures vigilance and visual attention, the Penn Letter N-
Back test which measures working memory, and the Penn emotion recognition task which 
measures affect perception, were included  
Table 2. Procedure and measures of the BACS and Penn CNP protocols used in the YouR study 
Assessment 
Name of 
task Procedure 
Time for 
task 
(in seconds) Measure Range 
BACS       
Verbal 
memory 
List 
learning 
(Version 
1) 
List of 15 words is read to 
participant and asked to recall 
as many as possible in any 
order. Procedure repeated five 
time.  
-  
Number of 
correct words 
recalled per 
trial, cumulated  
0 – 75 
Working 
memory 
Digit 
sequencin
g task 
Participants are read blocks of 
randomly ordered numbers, 
which steadily increase in 
amount during the trial. 
Participants are asked to order 
the number from lowest to 
highest  
-  
Number of 
correct 
responses 
0 – 28 
 
Motor speed 
Token 
motor task 
100 plastic tokens were spread 
out across a table. Participants 
were asked to place two tokens 
(one in each hand) into a 
container in the middle, and 
repeat as many as possible in 
the time given.   
60 
Number of 
tokens correctly 
placed in the 
container 
0 – 100  
Table 2 cont. below  
 
48 
 
Assessment 
Name of 
task Procedure 
Time for task 
(in sec.) Measure Range 
BACS      
Attention 
and 
Processing 
Speed  
Symbol 
coding  
Nine symbols matching to 
the numbers 1-9 were given 
as a key to the participant, 
and they were asked to 
translate the lines of the 
symbols into the numbers  
1-9  as quickly as possible. 
90 
Number of 
correct symbols 
input 
0 – 110  
Verbal 
fluency 
Semantic 
fluency 
Participants were asked to 
name as many of a 
category (animals) as 
possible.  
60 
Number of 
different 
animals listed 
∞ 
 
Letter 
fluency 
In two separate trials, 
participants were asked to 
name as many words 
starting with the letter  
(S, F)  
60 
Number of 
different 
words listed 
∞ 
Penn CNP      
Vigilance 
and visual 
attention  
Penn 
Continuous 
Performance 
task 
A series of red vertical 
and horizontal lines 
composed of 7 segments 
flash in front of the 
participant(stimulus), 
followed by a blank 
screen. Participants press 
the space bar if the lines 
from a complete number 
or complete letters  
.3/ 
stimulu
s 
 
1/item 
 
360 
total 
Number to 
true positive 
responses, 
response time 
of correct 
responses 
0 - 
360 
Affect 
perception 
Penn 
emotion 
identificatio
n task 
Participants are shown a 
face, and must respond if 
they believe the facial 
expression is happy, sad, 
angry, fearful or neutral. 
This protocol is repeated 
40 times. The faces are 4 
men & 4 women each 
showing each expression  
-  
Correct 
responses, 
response time 
of correct 
responses 
0 - 40   
Working 
memory  
Penn Letter 
N-Back test 
A Letter flashes on the 
screen (stimulus) followed 
by a blank screen. 
Participants press space 
bar when one of the 
following pattern rules 
(0,1,2) are met: 0 = 
current stimulus is present, 
1 = the same letter is 
repeated twice in a row, 2 
=  the letter shown before 
the previous letter, 
matches the current one  
.5/ 
stimulu
s 
 
2.5/item 
 
337.5 
total 
Number to 
true positive 
responses, 
response time 
of correct 
responses 
0 - 
135 
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2.8 Statistical analysis  
All statistical analysis were performed using R (R Core Team, 2019). Level of significance was 
set as 0.05 (two-tailed). 
Three univariate measures were considered against the outcome measures: duration, gender and 
age at onset. DUPrS is the primary measure and is calculated by the number of months from 
onset until the date of the baseline interview. Gender and birth date are reported as demographic 
measures. Age of onset was calculated by subtracting age at baseline in months from months 
since onset of symptoms. These secondary measures were also considered in conjunction with 
duration to see the full effect of DUPrS on cognition and function measures.  
To determine the effect of DUPrS on outcome measures, the CAARMS and SPI-A symptom 
with the longest continuous duration reported by each person was entered into the analysis, in 
line with previous studies in the field (Carrión et al., 2016; Chon et al., 2015; Nelson et al., 2016; 
Schultze-Lutter et al., 2010; Zhang et al., 2017; 2018a, b). In individuals who reported both APS 
and BS symptoms these were recorded separately. 
To assess the relationship between onset of  BS and APS, z-score transformations of the duration 
since the first onset APS and BS were conducted. This calculation was only done for individuals 
who had reported both. The z-scores were converted using the means and standard deviations of 
the duration of symptoms in the CHR-P group (APS and BS, conducted separately for the 
respective group). This method was applied to adjust for outliers (see Schultze-Lutter et al., 
2010).  
BACS and Penn CNP data was converted from raw data into standardized z-scores for each 
cognitive domain. The z-scores were converted using the means and standard deviations of the 
healthy control group, collected as part of the YouR study. For the BACS measures, the control 
group mean, and standard deviation were divided based on gender, and comparisons were also 
based against the respective genders. This is to keep in line with previous studies reporting 
significant gender differences in BACS measures scores (Keefe et al., 2004). The BACS 
composite score was calculated for each participant by averaging all six z-scores obtained on the 
cognitive measures, and then re-standardizing the average score by the same method discussed 
above (Keefe et al., 2004).  
The overall variance explained by the models obtained through stepwise linear and logistic 
regressions was measured by the R2 statistic.  
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3 Results 
A summary of duration of all symptoms reported is in the appendix (Appendix Table 1). In line 
with previous literature, the analysis was conducted on the earliest onset sub-threshold symptom. 
This was determined from the reported symptom subtype with the longest duration, for APS and 
BS, separately.  
Differences in demographic and functional information between individuals with APS and BS 
were analysed using Bartlett’s test for continuous data, chi-square tests for categorical data, and 
non-parametric Kruskal-Wallis H tests for ordinal variables. 
Table 3. Summary of Demographic and Clinical Variables in Relations to Duration of APS and 
BS. 
 APS BS df K2/H/X2 p 
Number of participants 109 89    
Gender, f(%) 78(71.56) 60(67.42) 1 X2  = 0.8 0.4 
Age at baseline, median(range)   20(16-34) 21(16-34) 1 H = 0.2 0.6 
Age at onset, median(range)  18(4-34) 17(5-30) 1 H = 0.3 0.6 
years in education, median(range) 15(8-26) 15(10-26) 1 H = 0.4 0.6 
UK citizen, N (%)   1 X2  = 0.4 0.5 
Mean duration, in months 43 53 1 K2 = 0.6 0.2 
Median duration, in months 27 (1-246) 42 1 H = 1 0.2 
GAF, median (range) 58(21-89) 58(21-95) 1 H = 3  0.1 
GF: Role, median(range) 8(4-9) 8(4-9) 1 H = 0.9 0.4 
GF: Social, median(range) 8(5-9) 8(5-9) 1 H = 0.8 0.4 
Medication, N(%)   1 X2 = 0.2 0.6 
 Anti-psychotic 2(2) 1(11)    
 Mood stabiliser 1(1) 0    
 Anti-depressant 25(23) 18(20)    
 Anti-convulsant 0 1(1)    
 Other 10(9) 10(11)    
 Multiple 16(15) 13(15)    
Diagnosis, N (%)   1 X2 =0.3 0.6 
 Anxiety disorder 76(70) 56(63)    
 Mood disorders 73(67) 58(65)    
 Eating disorders 12(11) 7(8)    
 Suicide risk 59(54) 48(54)    
 Alcohol dependence/abuse 33(30) 25(28)    
 Substance dependence/abuse 18(17) 10(11)    
Abbreviations APS = attenuated psychotic symptoms, BS = basic symptoms. X2  = Pearson’s Chi-squared test, K2 = Bartlett test of  
homogeneity of variances, H = Kruskal-Wallis rank sum test.  
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No significant differences were found between participants who reported APS compared to 
participants who reported BS in age at baseline, age at onset, gender, years of education, 
citizenship, duration of symptoms, functioning, medication or diagnosis (Table 3).  
Table 4. Baseline CHR-P CAARMS and SPIA Symptoms   
 
 
Number of 
participants 
Mean 
duration, 
in months 
Median 
duration, 
in months 
(range) 
Mean age 
at onset, 
in years 
Gender 
f(%) 
APS        
 Unusual thought content  20 37.55  24(1-121) 18.12 14(70) 
 Non-bizarre ideas 49 53.84 42(1-246) 17.82 35(71.4) 
 Perceptual abnormalities 39 32.59 12(2-173) 17.67 28(71.8) 
 Disorganised speech 1 48 48 25 1(100) 
BS       
 Inability to divide attention  8 25.88 15(10-86) 20.59 5(62.5) 
 Thought interference  2 47 47 19.08 1(50) 
 Thought blockage  20 69.45 50.5(6-180) 17.31 11(55) 
 Disturbances in receptive speech 5 39.4 33(1-84) 15.92 5(100) 
 Disturbances in expressive speech  10 29.7 24(6-77) 21.03 7(70) 
 Thought pressure  3 75.33 59(33-134) 15.72 3(100) 
 Unstable ideas of reference  2 98 98(63-133) 11.83 1(50) 
 Thought perseveration  1 84 84 11 1(100) 
 Decreased ability to discriminate… 1 94 94 8.17 1(100) 
 Captivation of attention by details… 2 29.5 29.5(20-39) 18.54 2(100) 
 Derealization  6 73 72.5(12-120) 16.17 4(66.67) 
 Visual perception disturbances 12 44.08 19(1-187) 16.91 9(75) 
 Acoustic perception disturbances 17 52.82 49(7-139) 16.19 10(58.2) 
Abbreviations Captivation of attention by details... = Captivation of attention by details in the visual field, decreased ability to 
discriminate... = Decreased ability to discriminate between ideas and perception, fantasy and true memories 
 
There was a large variation in the number of individuals who experienced different CAARMS 
symptoms (range = 1 – 49), similarly there was a significant difference in the number of 
individuals who experienced different SPIA symptoms (range = 1 – 20). There were notable 
differences in the duration of individual CAARMS symptoms (m = 32.59 – 53.84, med = 12 - 
48) and SPIA symptoms (m = 25.88 – 98, med = 15 - 98) (Table 4). 
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 Figure 2. Mean and median duration of first onset symptoms reported by CHR-P at baseline. 
              
Blue = SPI-A symptom subtypes, Red = CAARMS symptom subtypes. Abbreviations: B1 = Inability to divide attention, C2 = Thought interference, C3 = Thought blockage, C4 = Disturbance of receptive speech, C5 = 
Disturbances of expressive speech, D3 = Thought pressure, D4 = Unstable ideas of reference, O1 = Thought preservation, O2 = Decreased ability to discriminate between ideas/perception and fantasy/true memories, O7 
= Captivation of attention by details of the visual field, O8 = Derealization, AcoDist = acoustic perception disturbances, VisDist = visual perception disturbances, UTC = unusual thought content, NBI = non-bizarre 
ideas, PA = perceptual abnormalities, DS = disorganized speech. 
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3.1 Relationship between attenuated psychotic symptoms and basic symptoms  
Previous research has assumed that BS precede the onset of APS (Fusar-Poli et al., 2013; Häfner 
et al., 2003; Schultze-Lutter et al., 2016). To test if this relationship is found in the current CHR-
P group, the first onset APS and BS symptom, in participants reporting both symptoms, were 
compared.  
To adjust for outliers, the data was transformed to z-scores (see Schultze-Lutter, Ruhrmann, 
Berning, Maier, and Klosterkötter, 2010).  Z-score transformations were calculated based on the 
earliest onset BS and APS, calculated from the reported month of onset to baseline interview 
date. As is standard in using z-scores, data points > ± 3 SD were rounded to ± 3 (Shiffler, 1988).  
Analysis of the relationship between APS and BS onset was conducted using paired t-tests. 
Robust linear regression was also used to analyse a relationship between BS onset and APS onset 
as a measure which accounted for outliers.  
Figure 3. Scatterplot and loess smooth line of the relationship between the duration of APS and 
BS   
 
Abbreviations F = female, M = male, APS = attenuated psychotic symptoms, BS = basic symptoms  
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48.4% of the sample reported BS onset occurring prior to APS onset (n = 31), 37.5% reported 
APS onset prior to BS (n = 24), and 14.1% reported APS and BS onset (n = 9) occurring in the 
same month. In measures of time differences, no relationship was found between APS and BS 
onset (paired t-test: t = 0.02, df = 63, p = 1). The mean difference in the duration length was 
0.0035 months (95%CI [-0.31 to 0.32]). Robust linear regression analysis which accounted for 
outliers also failed to find a relationship (robust regression: B = 0.056, SE = 0.082, t-value = 
6.89, p = 0.5).  
Secondary analysis was conducted that examined the relationship between short or long BS 
duration and onset of APS. This was conducted based off reported between group differences 
found in short and long duration of sub-threshold symptoms (B. Nelson et al., 2016; Zhang et 
al., 2017). This was conducted on the z-score transformation as >/< 1 (≈ 99.7 months). Short BS 
duration showed no significant relationship (paired t-test: t = -1, df = 50, p = 0.3, 95%CI [-0.287, 
0.093]), even when outliers were accounted for (robust regression: B = 0.267, SE = 0.142, t-
value = 1.879, p = 0.07). Long BS duration did show a relationship (paired t-test: t = 3, df = 4, p 
= 0.04, 95% CI [0.12 – 2.39]), which persisted when outliers were accounted for (robust 
regression: B = 0.310, SE = 0.032, t-value = 9.598, p = 0.002). 
3.1.1 Influence of Gender, Age of onset and Education  
Previous findings had reported an influence of age at onset and years of education on onset of 
BS and APS (Schultze-Lutter et al., 2010; Schultze-Lutter, Rahman, et al., 2015). In addition, 
evidence suggests that there are gender differences in duration of psychotic symptoms, with 
studies reporting that males experience longer duration of untreated illness (DUI) compared to 
females (Rietschel et al., 2015). Barajas et al., (2015) showed that this relationship also occurred 
in CHR-P groups, with male participants reporting earlier onset and longer sub-threshold 
symptoms.  
3.1.1.1 Education  
CHR-P were divided into groups based on level of education (3rd level/ no 3rd level) to measure 
if between group differences previously reported (Schultze-Lutter et al., 2010) occurred in this 
sample. Individuals not in 3rd level education reported no significant relationship between APS 
and BS onset (paired t-test: t = 0.4, df = 7, p = 0.7, 95% CI [ -0.78, 1.14]), including when outliers 
were accounted for (robust regression: B = -0.037, SE = 0.195, t-value = -0.191, p = 0.9). Results 
for individuals in third level education similarly failed to show a significant effect (paired t-test: 
t = -0.1, df = 54, p =0.9, 95%CI: [-0.37, 0.33]; robust regression: B = 0.068, SE = 0.094, t-value 
= 0.722, p = 0.5). 
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3.1.1.2 Age at onset  
CHR-P were divided by age at onset (>/< 18 years of age at onset of either symptom type). 
Neither group showed a significant relationship between APS and BS onset (paired t-test: < 18 
years at onset: t= 0.1, df = 40, p =0.9, 95% CI [-0.4, 0.44]; > 18 years paired t-test: t= -0.1, df = 
22, p =0.9, 95% CI: [-0.53, 0.48]), including when robust measures were used (robust regression: 
< 18 years at onset:  B = -0.015, SE = 0.136, t-value = -0.113, p = 0.9; > 18 years at onset: robust 
regression: B = -0.016, SE = 0.085, t-value = -0.193, p = 0.8). 
3.1.1.3 Gender  
Male participants did not show a statistical relationship between APS and BS duration (paired t-
test: t= -0.01, df = 18, p = 1, 95% CI: [-0.69, 0.68]) even when outliers were accounted for 
(robust regression: B = -0.055, SE = 0. 188, t-value = -0.293, p = 0.8). The same result was 
obtained for female participants (paired t-test: t= 0.04, df = 44, p =1, 95% CI: [-0.36, 0.37]) or 
onset (robust regression: B = 0.094, SE = 0.093, t-value = 1.021, p = 0.3). 
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Table 5.  Summary of the paired t-tests and robust linear regressions conducted between APS-BS duration and onset. 
 
Abbreviations n = number of participants, df = degrees of freedom, t = t-value, MD = mean difference, p = p-value, CI = confidence intervals, B = unstandardized estimate, SE = standard error, F =f test 
 
 Paired t-test  Robust regression  
 n df t MD p 95% CI  B SE t-value F p 
Whole sample 64 63 0.02 0.00 1 -0.31, 0.32  0.056 0.082 0.689 0.5 0.5 
 < 1  51 50 -1 -0.097 0.3 -0.28, 0.093  0.267 0.142 1.879 3 0.07 
> 1  13 4 3 1.3 0.04 0.12, 2.39  0.310 0.032 9.598 112 0.002 
Male only 19 18 -0.01 -0.004 1 -0.69, 0.68  -0.055 0.188 -0.293 0.09 0.8 
Female only  45 44 0.04 0.007 1 -0.36, 0.37  0.094 0.093 1.021 1 0.3 
< 18 years 41 40 0.1 0.02 0.9 -0.4, 0.44  -0.015 0.136 -0.113 0.01 0.9 
> 18 years  23 22 -0.1 -0.026 0.9 -0.53, 0.48  -0.016 0.085 -0.193 0.04 0.8 
No 3rd level education 9 7 0.4 0.18 0.7 -0.78, 1.14  -0.037 0.195 -0.191 0.04 0.9 
3rd level education 55 54 -0.1 -0.021 0.9 -0.37, 0.33  0.068 0.094 0.722 0.5 0.5 
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3.2 Impact of duration of prodromal symptoms on functional outcomes 
GAF is collected at baseline and completed by all 134 participants. 15 individuals did not 
complete a second baseline interview, so were excluded from analysis on role and social 
functioning 
Linear regressions were used to conduct analysis between duration, gender, or age of onset and 
the GAF score. Multivariate linear regression was conducted to measure models of the 
interactions between duration and gender, and duration and age of onset, on GAF score.  
The GF: Social and Role scale measures showed narrow ranges (social: range = 4 – 9, role: range 
= 5 – 9), meaning the measures failed to meet the assumptions of parametric measures. Quantile 
regressions were used to conduct analysis between duration, gender, and age of onset on role 
and social functioning. Multivariate multiple regressions in quantile regressions need larger 
samples of data (Koenker, 2005) than the current study, so were not conducted.  
Table 6. Effect of duration of prodromal symptoms on functioning outcomes. 
  B SE β t 95% CI R2 p 
APS 
        
 GAF -0.015 0.023 -0.063 -0.65 -0.06, 0.03 -0.005 0.51 
 GF: Role 0.000 0.004 - 0.00 - - 1.0 
 GF: Social 0.000 0.003 - 0.00 - - 1.0 
BS         
 GAF -0.035 0.031 -0.121 -1.13 -0.10, 0.03 0.0033 0.26 
 GF: Role 0.000 0.003 - 0.00 - - 1.0 
 GF: Social 0.000 0.002 - 0.00 - - 1.0 
Abbreviations GAF = global assessment of functioning, GF: Role = global functioning: role scale, GF: Social = global functioning: social 
scale, B = unstandardized estimate, SE = standard error, β = standardized estimate, t = t value CI = confidence intervals, p = p-value 
 
Duration of APS or BS as a single main effect was not found to be significant in GAF scores, 
role functioning or social functioning (Table 6). Summary of effect of gender and onset are in 
the appendix (Appendix Table 2).  
No significant effect was found by including gender or age of onset and APS duration on GAF 
scores. Similarly, no effect was found on either model with BS duration on GAF scores. Both 
measures are reported in the appendix (Appendix Table 3). Multivariate quantile regressions 
requires larger sample sizes (Koenker, 2005) than is available in the current study, so these 
models were not compared to GF: Role or Social measures. 
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Previous findings have reported differences in functioning depending on length of DUPrS  
(Nelson et al., 2016; Zhang et al., 2017, 2018b). To measure if this effect existed in this sample, 
symptom length was divided into short and long for APS and BS (Table 7). The separation was 
divided based on the median duration for APS (MED = 27 months) and BS (MED = 42 months). 
Table 7. Effect of duration of prodromal symptoms on functioning outcomes, divided by 
symptom length. 
  B SE β t 95% CI R2 p 
APS 
        
Short         
 GAF -0.320 0.211 -0.206 -1.52 - 0.74, 0.1 0.0425 0.13 
 GF: Role 0 0.039 - 0 - - 1.0 
 GF: Social 0.045 0.022 - 2.04 - - 0.047 
Long         
 GAF 0.011 0.033 0.047 0.34 - 0.054, 0.076 0.0022 0.74 
 GF: Role -0.0052 0.0045 - -1.16 - - 0.25 
 GF: Social 0 0.0052 - 0 - - 1.0 
BS      
   
Short         
 GAF -0.305 0.201 -0.228 -1.51 -0.71, 0.1 0.0518 0.14 
 GF: Role -0.029 0.022 - -1.35 - - 0.18 
 GF: Social -0.037 0.026 - -1.40 - - 0.17 
Long          
 GAF -0.014 0.040 -0.056 -0.36 -0.095, 0.066 0.0031 0.72 
 GF: Role -0.0072 0.0052 - -1.39 - - 0.17 
 GF: Social -0.0072 0.0052 - -1.38 - - 0.18 
Abbreviations GAF = global assessment of functioning, GF:Role = role functioning, GF:Social = social functioning, B = 
unstandardized estimate, SE = standard error, β = standardized estimate, t = t value CI = confidence intervals, p = p-value 
Divided by duration, shorter APS was associated with slight negative effects on social 
functioning (B = 0.045, p = 0.047), though this finding was not significant in the long APS group 
(B = 0, p = 1.0) (Table 7). No significant effect of APS or BS duration was found for any other 
measure of functioning. Summary of effect of gender and onset are in the appendix (Appendix 
Table 4). 
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3.3 Impact of duration of prodromal symptoms on cognitive functioning 
16 CHR-P participants did not complete the third screening and were excluded from the analysis 
on cognition measures. Cognition data was converted from raw data into standardized z-scores. 
The z-scores were converted using the means and standard deviations of the healthy control 
group. For the BACS measures, the control group mean, and standard deviation were divided 
based on gender, and comparisons were also based against the respective genders, in line with 
previous research (Keefe et al., 2004). The BACS composite score was calculated for each 
participant by averaging all six z-scores obtained on the cognitive measures, and then re-
standardizing the average score by the same method discussed above (Keefe et al., 2004).  
F-tests were conducted to compare cognition scores between of CHR-P to healthy controls, 
Cohen’s d was used to measure effect size.  
Table 8. Results of individuals with APS and BS in Neurocognitive and Social Cognitive 
Measures compared to a healthy control group.  
 
Controls 
(n = 57) 
CHR-P 
(n = 136) df F (95%) CI p Cohen’s d 
 M SD M SD      
BACS           
Verbal memory 0 1 -0.23 1.22 56 1 0.92, 2.23 0.1 -0.2 
Working memory 0 1 -0.07 1.26 56 2 0.99, 2.41 0.05 -0.06 
Motor speed 0 1 -0.79 1.12 56 1 0.78, 1.89 0.4 -0.73 
Attention & processing 
speed  0 1 -0.49 1.16 56 1 0.84, 2.05 0.2 -0.44 
Verbal fluency  0 1 -0.14 0.62 56 0.8 0.49, 1.19 0.2 -0.29 
Executive function 0 1 -0.04 1.36 56 2 1.1, 2.8 0.01 -0.033 
BACS composite score 0 1 -0.64 1.51 56 2 1.4, 3.4 < 0.001 -0.46 
Penn CNB          
Emotion recognition 
accuracy  0 1 -0.16 1.00 56 1 0.62, 1.50 0.9 -0.15 
Emotion recognition RT 0 1 0.43 1.28 56 2 1.0, 2.5 0.03 0.36 
Working memory accuracy 0 1 -0.29 1.15 56 2 1.1, 2.8 0.01 -0.3 
Working memory RT  0 1 -0.09 0.80 56 0.7 0.41, 1.00 0.05 -0.1 
Attention accuracy  0 1 -0.37 1.29 56 2 1.0, 2.5 0.04 -0.3 
Attention RT 0 1 -0.13 0.88 56 1 0.6 1.5 0.8 -0.18 
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The CHR-P group showed significant differences compared to healthy controls, and performed 
worse in all measures of working memory, executive function, attention accuracy and BACS 
composite score (Table 8). CHR-P preformed slightly statistically better than controls in the 
emotion recognition task in reaction time scores (Table 8).  
Univariate MANOVAs were conducted to examine any effect duration of subthreshold 
symptoms, gender, or age of onset had on measures of cognition.  Multivariate MANOVAs were 
conducted to measure the models of the interaction between duration and gender, and duration 
and age of onset, on neurocognitive measures. Bonferroni correction was applied to adjust for 
multiple comparisons. 
3.3.1 Impact of attenuated psychotic symptom duration on Cognitive Outcomes  
Table 9. Analysis of the Effect of APS Duration on Cognition  
 B SE β t 95% CI R2 p 
BACS         
Verbal memory 0.000 0.002 0.000 0.00 -0.005, 0.005 0.000 0.997 
Working memory 0.001 0.003 0.062 0.56 -0.004, 0.007 0.003 0.58 
Motor speed -0.005 0.002 -0.17 -1.96 -0.009, 0.000 0.038 0.05 
Attention & processing 
speed 
-0.001 0.002 -0.04 -0.4 -0.006, 0.004 0.002 0.66 
Verbal fluency -0.002 0.001 -0.07 -1.38 -0.004, 0.007 0.019 0.17 
Executive function 0.000 0.003 0.036 0.15 -0.005, 0.006 0.000 0.88 
BACS composite score -0.001 0.003 -0.05 -0.44 -0.007,0.005 0.002 0.66 
Penn CNP        
Emotion recognition 
accuracy  
0.001 0.002 0.035 0.34 -0.003, 0.005 0.001 0.73 
Emotion recognition RT 0.003 0.003 0.124 1.22 -0.002, 0.008 0.015 0.23 
Attention accuracy  0.000 0.003 -0.09 -0.17 -0.006, 0.005 0.000 0.86 
Attention RT -0.003 0.002 -0.17 -1.7 -0.007, 0.001 0.029 0.09 
Working memory accuracy -0.002 0.002 -0.08 -0.77 -0.007, 0.003 0.006 0.44 
Working memory RT  -0.001 0.002 -0.05 -0.48 -0.004, 0.003 0.002 0.63 
Abbreviations: RT = reaction time, B = unstandardized estimate, SE = standard error, β = standardized estimate, t = t value 
CI = confidence intervals, p = p-value 
Longer APS duration was associated with worse motor speed scores, and explained 4% of the 
variance in the sample (Table 9). The findings showed very marginal negative effects, and the 
findings are moderately significant (B = -0.005, p = 0.05, 95%CI [-0.009, 0.000]). Summary of 
effect of gender and onset are in the appendix (Appendix Table 5.1).  
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Figure 4. Interaction effect of duration of APS and age of onset on motor speed 
 
Onset age divided into three quantiles (25th, 50th, 75th), reported in years.  
A model including APS duration and age at onset of APS symptoms was found to be significant 
for motor speed. The remaining findings are reported in the appendix (Appendix Table 6.3).  The 
model accounted for 9% of the variance in the sample and was significant (p = 0.04). This finding 
indicates that those who were older at the onset  of symptoms were more affected by longer APS 
duration compared to individuals who were younger when symptoms onset, and this interaction 
resulted in worse motor speed scores (B = -0.001, p = 0.05, 95%CI [-0.0021, 0.0002])  
No significant relationship was found between APS duration and cognition measures when 
gender was added to the model (Appendix Table 6.1).  
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3.3.2 Impact of  basic symptom duration on cognitive outcomes  
Table 10. Analysis of the Effect of BS Duration on Cognition 
 
B SE β t 95% CI R2 p 
BACS         
Verbal memory -0.012 0.020 0.0072 -0.59 -0.006, 0.006 0.0097 0.56 
Working memory 0.013 0.017 0.14 0.75 -0.002, 0.010 0.0154 0.46 
Motor speed 0.020 0.018 -0.13 1.09 -0.006, 0.005 0.0318 0.28 
Attention & processing speed 0.006 0.018 0.1 0.33 -0.003, 0.009 0.0031 0.74 
Verbal fluency 0.020 0.010 0.29 2.01 -0.003, 0.004 0.0341 0.05 
Executive function -0.008 0.024 -0.097 -0.35 -0.008, 0.005 0.0102 0.73 
BACS composite score 0.010 0.022 0.065 0.47 -0.005, 0.009 0.0062 0.64 
Penn CNP        
Emotion recognition 
accuracy  
0.000 -0.020 0.003 -0.18 -0.006, 0.005 0.0004 0.86 
Emotion recognition RT -0.003 -0.108 0.003 -0.96 -0.010, 0.003 0.0117 0.34 
Attention accuracy  0.002 0.081 0.003 0.72 -0.004, 0.009 0.0066 0.48 
Attention RT -0.020 -0.196 0.017 -1.22 -0.008, 0.002 0.0385 0.23 
Working memory accuracy -0.002 -0.081 0.003 -0.72 -0.008, 0.004 0.0065 0.48 
Working memory RT  -0.001 -0.051 0.002 -0.45 -0.005, 0.003 0.0026 0.65 
Abbreviations: RT = reaction time, B = unstandardized estimate, SE = standard error, β = standardized estimate, t = t value 
CI = confidence intervals, p = p-value 
Shorter BS duration was associated with worse verbal fluency scores (B = -0.02, p = 0.05) and 
explained 3% of the variance in the sample (Table 10).  Effect of gender and age of onset are 
reported in the appendix (Appendix Table 5). 
A model including gender and duration of BS failed to find significant effect of the model on 
most cognition measures, which is reported in the appendix (Appendix Table 6.2). Two measures 
using this model found an effect from this interaction term; verbal fluency and working memory 
accuracy (Table 11).  
In the verbal fluency measure, the whole model was significant (p < 0.0001), including when 
adjusted for multiple comparisons. The model showed in male participants shorter BS was 
associated with worse verbal fluency (B = -0.037, p = 0.0041) compared to female participants 
(Table 11). This model explained 71% of the variance of the scores in verbal fluency between 
participants. However, the main effect showing significance in this model was not duration, and 
gender as a single main effect explained 58% of the variance (Appendix Table 5.1).  
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In the working memory accuracy measure, the whole model explained 6% of the variance, but 
was not significant (p < 0.5) (Table 11). One measure in the interaction was significant, and 
showed when the variance created by gender was accounted for, longer duration showed a 
marginal negative effect on working memory accuracy (B = -0.011, p = 0.05). The interaction 
was near significance, and showed that male participants performed relatively worse compared 
to female participants (B = 0.012, p = 0.6). 
A model of the interaction between BS duration and age of onset also showed significance in 
BACS composite score, but failed to find an effect on any other measure of cognition. These 
finding are reported in the appendix (Appendix Table 6.4). The model explained 12 % of the 
variance, but was not significant (p < 0.5) (Table 11).  Short BS duration was shown to have a 
negative relation to BACS composite scores (B = -0.201, p = 0.04). The interaction was also 
significant (p = 0.05), and showed that those who were younger when symptoms onset were 
more effected by longer BS duration compared to individuals who were older when symptoms 
onset, and this interaction resulted in this group having worse overall BACS scores (B = -0.001, 
p = 0.05, 95%CI [-0.0021, 0.0002]) (Table 11).  
Table 11. Analysis of the Effect of BS Duration and Gender/Age of Onset on Cognition 
  B SE β t Pr(>|t|)  R2 p 
BACS         
Verbal fluency           
 Duration 0.037 0.009 0.13 3.94   0.0004 
} 
  
 Gender 1.740 0.264 0.92 6.6 < 0.0001 0.714 < 0.0001 
 Duration*Gender -0.037 0.012 -0.12 -3.1   0.0041   
BACS composite score        
 Duration 0.201 0.096 -0.079 2.11 0.04 
} 
  
 Onset 0.184 0.114 -0.141 1.62 0.12 0.122 <0.5 
 Duration*Onset -0.010 0.005 0.043 -2.07 0.05   
Penn CNP         
Working memory accuracy        
 Duration -0.011 -0.395 0.005 -1.96 0.05 
} 
  
 Gender -0.388 -0.149 0.457 -0.85 0.40 0.061 < 0.5  
 Duration*Gender 0.012 0.453 0.006 1.88 0.06   
Abbreviations: B = unstandardized estimate, SE = standard error, β = standardized estimate, t = t value CI = confidence 
intervals, p = p-value 
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4 Discussion 
The main aim of the current study was to examine the duration of prodromal symptoms in a non-
help seeking population to establish differences and similarities in DUPrS with previous data 
from help seeking CHR-P samples.  To this end, the duration length of APS and BS onset as 
well as their effects on outcome measures were investigated.  
Three key questions were asked: - 
1. Does the assumed relationship of BS onset preceding APS onset occur in a CHR-P 
sample? 
2. Is there an effect of duration of APS or BS, on functioning, and does this differ in those 
with  longer or shorter duration? 
3. Is there effect of duration of APS or BS, on cognition? 
Three key findings emerged from this study. First, this study failed to find evidence for BS onset 
preceding APS onset in this CHR-P sample, despite the current hypothesis of BS reflecting 
immediate symptomatic expression of the neurobiological processes underlying schizophrenia, 
and APS being a secondary consequence of poor coping to BS (Schultze-Lutter et al., 2016). 
Secondly, this study failed to find a main effect of DUPrS on either  outcome measure. The study 
finding no effect of DUPrS on functioning contrasts with DUP research which has reported 
consistent evidence that longer DUP is associated with worse outcomes (Penttilä et al., 2014). 
This difference between findings may offer validation to current theories regarding the critical 
period theory of psychosis. The study failed to find an effect of duration on cognition, which 
was inconsistent with some previous findings of DUP (Rapp et al., 2013), but consistent with 
findings on DUPrS (Chon et al., 2015). Finally, this study suggested preliminary evidence that 
in community CHR-P samples, duration of symptoms is significantly longer then in clinical 
studies.  
4.1 The relationship between basic symptom onset and attenuated psychotic 
symptom onset in a CHR-P sample.  
This is the first study to consider the relationship between BS and APS onset in a CHR-P sample. 
The previous study on this measure in an FEP sample (Schultze-Lutter et al., 2010) reported BS 
onset prior to APS. The current study found no significant relationship between BS onset and 
APS onset (p = 1.00, 95% CI = [-0.31, 0.32]) even when outliers were accounted for. 
Accordingly, this study does not confirm the current hypothesis that BS are the manifestation of 
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psychosis-risk and that APS are secondary consequence of poor coping mechanisms in response 
to the BS (Schultze-Lutter et al., 2016) 
While there was no overall relationship, there was some evidence of a moderate trend when 
considering short and long duration of BS symptoms separately. Only the long BS duration 
sample showed a statistically significant relationship of BS onset preceding APS onset. Analysis 
for between group differences based on gender, age at onset, and years of education all failed to 
find evidence of BS onset preceding APS onset in any of the groupings. All measures had narrow 
confidence intervals around a null value, suggesting strong evidence that BS onset had no 
relationship to APS onset. 
Overall these findings challenge the hypothesis of BS occurring prior to APS. In fact, APS onset 
preceded BS onset in a significant portion of the sample (37.5%, n = 24), and there was no 
significant evidence for a time difference between BS and APS onset across the sample. These 
findings were consistent when variables previously reported to effect recall of DUPrS, age at 
onset and years of education, were accounted for. The findings of the current paper challenges 
the central assumption that APS constitute a response towards more fundamental BS (Schultze-
Lutter, 2009). 
Secondly, this analysis differs from the currently used staging model of the CHR-P state. This 
model classifies presence of only BS as the early at-risk mental stage, and presence of both BS 
and APS as the late at-risk mental stage (Fusar-Poli et al., 2013). The findings of this paper 
appear to suggest that the assumed stages of this model do not reflect the trajectory of all those 
who experience APS and BS.  
There are a number of potential explanations for the difference between the expected hypothesis 
and the findings of this study. One possibility is that the hypothesis of BS representing immediate 
symptomatic changes to the underlying biological processes, and APS being secondary 
responses (Schultze-Lutter et al., 2016), may not be accurate. This hypothesis was not primarily 
developed from neurobiological research. Rather, the hypothesis of BS was developed by  Huber 
and Gross (1989), and was based on evidence of presence of BS being correlated to higher rates 
of transition, and the continued presence of BS in those with schizophrenia. Their research has 
been validated, showing that presence of BS is associated with higher rates of transition in CHR-
P samples (Schultze-Lutter, Michel, et al., 2015), and that BS remain even in remission from 
psychosis (Schultze‐Lutter & Theodoridou, 2017).  
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These findings only show indirect evidence of the fundamental role of BS. Research into the 
neurobiological mechanisms of BS, and its role in APS and schizophrenia, is currently in the 
preliminary stages and has not conclusively shown evidence for this theory( Schultze-Lutter et 
al., 2016). The current study failing to validate these findings may offer preliminary evidence 
that this hypothesis, while observing a valid finding of the prevalence of BS in all stages of 
psychosis, may not have accurately assumed the role of BS in APS.   
However, previous research has shown evidence for BS onset preceding APS in an FEP sample 
(Schultze-Lutter et al., 2010), and appeared to support the hypothesis. A second explanation may 
be a difference between the groups studied in the current study and previous research. The 
hypothesis, and subsequent findings validating this relationship, were both conducted on FEP 
samples. In contrast, this study was completed on a CHR-P sample, the majority of whom did 
not transition (≈93% at 12 month follow up).  
The differences in the findings between the studies may be related to the risk of transition, with 
the current study representing a sample who are not at significant risk for transition. It is possible 
this between group difference in reported APS and BS onset may reflect different trajectories 
for those at genuine risk for psychosis, compared to those who will remit from CHR-P. This 
explanation does not provide a mechanism for how APS develops prior to BS, suggesting that 
while this between group difference may be significant, the current findings still produce 
evidence which does not confirm the current hypothesis describing APS as a response to BS.  
4.2 The impact of duration of prodromal symptoms on functional outcomes in short 
and long duration groups  
Functional deficits are a frequently reported outcome in CHR-P samples (Fulford et al., 2013; 
Salokangas & McGlashan, 2008) and are prevalent even in non-transitioned samples (Beck et 
al., 2019). Longer DUP and DUPrS have previously been found to have negative effects on 
functional outcomes (Penttilä et al., 2014; Zhang, et al., 2018a,b) 
The current study found no significant effect between APS and BS duration on role or social 
functioning. The only previous study to use GF: Role and Social as a measure compared to 
duration on a CHR-P sample (Carrión et al., 2016) also reported no effect of APS on functioning. 
Their study did find a relationship with the duration of negative symptoms .  
Based on previous findings which reported differences between short and long duration of 
symptoms (Nelson et al., 2016; Zhang et al., 2017; 2018b), the current study divided the sample 
into short and long duration of APS and BS and compared these groups with functioning. When 
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the current sample was divided into short and long duration of  APS and BS, in the short APS 
duration sample, duration was modestly associated with improvement in social functioning (B = 
0.045, p =0.047), but this was not the case in the long APS duration group (B = 0, p = 1.0). No 
effect of duration was found on role functioning, in either the short or long duration sample. No 
effect of BS duration was found on social or role functioning, even when divided into short and 
long duration samples. 
The current study found no association between longer duration of APS or BS on GAF scores. 
These findings remained consistent when the sample was divided into short and long duration. 
APS and BS duration in CHR-P samples has previously been reported to have a significant effect 
on GAF scores, with longer DUPrS associated with lower GAF scores (Fusar-Poli et al., 2009; 
Zhang, et al., 2018b). Fusar-Poli et al., (2009) found that a sample of individuals with reported 
BS at baseline followed up over 12 months showed a significantly lower GAF score compared 
to baseline. These effects were not explained by type of symptom or age of participant, but 
instead identified as being significantly correlated to the duration of the symptoms being present 
for the 12 months (β=70.375, p=0.008). Zhang and colleagues (2018b) reported that when a 
sample was divided into long and short APS ( >/<3 months), longer APS duration was associated 
with lower reported GAF scores, but failed to find an effect on present GAF scores in individuals 
with short or long DUPrS.  
While findings are inconsistent between samples, in general previous studies have reported 
DUPrS to show some effect on GAF scores and functioning, while the current study found no 
evidence for a relationship between duration of APS or BS and functioning measures. A potential 
explanation for the different findings between previous research and this study may be a 
difference between samples. Previous research on the effect of DUPrS on functional outcomes 
has all been conducted on clinical CHR-P samples (Carrión et al., 2016; Fusar-Poli et al., 2009; 
Zhang, et al., 2018a,b). In comparison the CHR-P YouR cohort is a non-help seeking sample, 
the majority of whom are currently in 3rd level education. This may mean that the study  has a 
bias in favour of recruiting  high functioning CHR-P participants. However, the CHR-P YouR 
cohort does show lower functioning compared to controls in the study (Haining et al., 2019).  
Overall, the inconsistent findings on the effect of longer DUPrS (Carrión et al., 2016; Fusar-Poli 
et al., 2009; Zhang, et al., 2018a,b), and the failure of the current study to find an effect of 
duration of APS or BS on any functioning measures is in contrast to previous DUP research. 
Research in DUP has consistently found evidence showing longer DUP has a moderate negative 
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effect on functional outcomes (Marshall et al., 2005; Murru & Carpiniello, 2018; Penttilä et al., 
2014). 
One explanation for this difference between DUP and DUPrS findings may be in relation to the 
critical period theory of psychosis. This theory  proposes that the first 2-3 years following onset 
of psychosis is associated with significant and rapid deterioration of neurological processes 
(Birchwood et al., 1998). It has been hypothesized the negative effects of longer DUP occur 
because of this delay in treatment during this critical period (Crumlish et al., 2009). Within this 
theory, DUPrS occurs prior to the critical period, and the different effect of DUPrS, compared 
with DUP, may demonstrate that the critical period only occurs following the first experience of 
a full psychotic symptom.  
However, the theory of a critical period as only occurring after onset of the first full psychotic 
experience has been disputed, with evidence showing that earlier intervention in CHR-P can 
improve outcomes in those who transition (Fusar-Poli et al., 2013; Malla et al., 2018). In 
addition, Longer DUPrS is associated with lower general functional scores in FEP individuals 
(Keshavan et al., 2003). The findings of this paper might provide preliminary support this theory, 
by demonstrating even in samples with significant lengths of DUPrS (>27 months APS or > 42 
months BS, ≈ > 2 years or >3.5 years), the duration does do not appear to have a significant 
negative effect on functioning in a low transition rate sample, compared to a transitioned FEP 
population.   
A second explanation may be related to a difference in sample, this study is the first study to 
examine duration of subthreshold symptoms in a community sample, not a help-seeking clinical 
sample. Previous studies on community sample CHR-P observed lower levels of symptom 
severity (Mills et al., 2017). This study failing to replicate previous findings of the relationship 
between duration and functioning may potentially indicate other differences between these 
groups. This may have important implications for future research; there is a currently an 
understudied group of individuals in the community, who experience symptoms at a frequency 
comparable to clinical CHR-P samples (Haining et al., 2019; McDonald et al., 2019; Mills et al., 
2017), but who may represent a differing population, and where current research of the trajectory 
and outcomes of CHR-P may not apply.  
4.3 The impact of duration of prodromal symptoms on cognition  
Cognitive deficits are a significant and stable feature of schizophrenia and CHR-P (Giuliano et 
al., 2012; Harvey & Bowie, 2003). In FEP and schizophrenia, longer DUP is associated with 
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deficits in visual memory, working memory and verbal memory (Amminger et al., 2002; Chang 
et al., 2013), though findings have been inconsistent (Rapp et al., 2013). Analysis of the effect 
of duration of APS as a single main effect on cognitive measures has only been conducted in 
one study (Chon et al., 2015), while a second study conducted measures of DUI (which includes 
DUPrS and DUP) (Rapp et al., 2013). Neither found a significant effect of DUPrS on cognition. 
The present study found that duration of APS had no main effect on the majority of 
neurocognitive and social cognition measures. Only one marginal main effect was found, that 
motor speed was negatively affected by longer duration (B = - 0.005, p = 0.05). Analysis of the 
effect of BS on cognition also showed no effect across the majority of the measures. One measure 
found longer BS duration was associated with slight improvements in verbal fluency scores (B 
= 0.02, p = 0.05). Chon et al., (2015) measured visual attention, verbal fluency, executive 
function, cognitive flexibility and theory of mind, a measure of social cognition. Their study 
failed to find a significant effect of APS duration on any of the reported measures. The current 
study similarly failed to find an effect of APS duration of executive function, attention, verbal 
fluency or social cognition. The only marginal significant finding, working memory, was not 
tested in previous research. Chon and colleagues (2015) did not analyse duration of BS as a main 
effect, and so the findings of BS duration having a marginal effect on verbal fluency could not 
be compared. Overall both studies showed no significant evidence for DUPrS having an effect 
on cognition.  
Research on DUP had noted a significant effect of independent variables of gender, age of onset 
and higher premorbid IQ that should be accounted for when analyzing the effect of DUP on 
outcome measures (Amminger et al., 2002). However, interaction models including gender and 
duration of APS or BS showed no significant effect across most models, despite significant 
between group differences being expected in some cognition measures (Keefe et al., 2004). 
Similarly, few models including age of onset and duration of APS or BS showed significance, 
despite evidence showing age of onset as a differential in outcomes between CHR-P groups 
(Häfner, 2000). The few models which were significant, showed very marginal effects on the 
cognition measures.   
The current research found limited evidence of any impact of the duration of APS or BS on 
neurocognitive measures. This occurred even when significant covariates of gender and age of 
onset (Häfner, 2000; Keefe et al., 2004) were accounted for. Rapp et al., (2013) failed to replicate 
findings reporting DUP having an effect on cognition. Their study then conducted a review of 
literature in the area, and found that across 18 studies measuring this relationship, only 5 reported 
70 
 
significant effects. Rapp and colleagues (2013) suggested that the lack of evidence for an effect 
of DUI on cognition measure might support the theory of psychosis as a neurodevelopmental 
disorder. This theory suggests that the cognitive deficits in schizophrenia precede the onset of 
symptoms (McGrath et al., 2003; Weinberger, 1987) and therefore cognition might have no 
connection to DUI. This study may be considered consistent with these findings.  
A different explanation by Goldberg et al., (2009), proposed that the lack of evidence for longer 
DUP having an effect on cognition, compared to the significant evidence of longer DUP having 
a negative effect on response to treatment, might provide evidence for two different 
psychological mechanisms. In this theory, psychotic experiences are conceptualized as learned 
behaviors which become more difficult to treat the longer, they are consolidated. In comparison, 
neurocognitive functioning is conceptualized as being comprised of moment-to-moment 
information processing, which is not dependent on the duration of the psychotic symptoms to be 
associated with deficits. This explanation could also be applied to DUPrS, and provide an 
alternative justification for the current study failing to find any significant effect of DUPrS on 
cognition. 
4.4 Length of DUPrS in non-help seeking sample 
Five previous studies have provided information on the DUPrS in CHR-P sample. Nelson and 
colleagues (2016) were reporting on the duration of APS of a cohort collected as part of the 
PACE study. This large longitudinal sample was broken down based on year of screening, to 
compare between differences of duration of sub-threshold symptoms. Yung et al., (2004) was 
also reporting on the duration of APS in the PACE sample, but did not create a between group 
design. Zhang et al., (2018a) reported on duration of APS in a CHR-P screened at the Shanghai 
Mental Health Centre. Carrión et al., (2016) reported on a sample gathered as part of the 
Recognition and Prevention (RAP) program, analyzing duration of positive and negative sub-
threshold symptoms in a CHR-P group. Chon and colleagues (2015) analyzed duration of APS 
symptoms in a CHR-P sample collected as part of an ongoing longitudinal study in the Seoul 
Youth Clinic.  
Two papers have studied duration of BS in a CHR-P sample (Fusar-Poli et al., 2009; 
Klosterkötter et al., 2001). However, neither study reported on the duration of the BS for the 
CHR-P sample. This means that comparisons between BS duration in previous findings and this 
current CHR-P sample cannot be done as part of this research.  
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Table 12. Duration of APS symptoms reported in previous work on DUPrS, compared to the 
YouR study.  
 
Cohort 
collected 
Mean 
duration, in 
months 
Median 
duration, 
in months Range 
YouR study 2016 – 2019  43 27 (1 - 246) 
Carríon, et al., (2016) 2000 – 2006  40.15 24.77 (2 - 192) 
Chon, et al.,(2015) 2005 – 2013  18.42 12.00 (1 - 60) 
Nelson, et al.,(2016)  1995 – 1997 18.57 13.12 (0 - 243) 
 1998 – 2000 16.09 6.00 (1 - 183) 
 2001 – 2003 10.41 6.07 (6 - 69) 
 2004 – 2006 14.83 8.00 (16 - 78) 
Yung, et al., (2004) 1995 – 1999  14.33 6.00 (0 - 134) 
Zhang, et al., (2018a)  2011 – 2013      - 3.7      - 
This evidence seems to support the possibility that a non-help seeking population experiences 
longer APS duration than previously reported durations of help-seeking CHR-P samples. The 
findings of the YouR study show that there is a sample of CHR-P who can be detected from 
community samples (McDonald et al., 2019), but that they may experience longer DUPrS than 
clinically referred CHR-P samples.  
One explanation for the longer mean and median duration of APS found in the YouR study, 
compared to previous findings, might be awareness of the general public of services from which 
the studies recruit. A majority of the previous CHR-P duration studies are based as part of larger 
mental health service programs i.e. the PACE study and the Shanghai Mental Health Centre  
(Nelson et al., 2016; Yung et al., 2004; Zhang et al., 2017;2018a, b). This means that there is 
likely wider awareness of these recruitment sites as mental health services. In comparison the 
YouR study recruited from a community sample, and received minimal CHR-P referrals (n = 8).  
The YouR study is tied to NHS Glasgow and Greater Clyde, but the screening and study took 
place in the psychology department at University of Glasgow, which may lack the same name 
recognition as previous clinically based studies. This could mean there was a delayed awareness 
of the YouR study in participants and may explain a difference in APS duration between the 
studies. 
A second explanation may be the focus of the previous studies on early intervention. A 
significant area of research in many of the previously reported help-seeking samples was the 
validity of earlier intervention methods in reducing transition rates (Chon et al., 2015; Nelson et 
al., 2016; Yung et al., 2004). This meant a priority of the studies was widespread outreach of the 
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programs, and earlier recruitment in younger samples. In comparison, while the YouR study 
used recruitment methods (flyers, emails, advertising), the aim of the study was not related to 
earlier targeted interventions. Instead recruitment followed a more open approach, inviting 
participants to a screening, following self-motivated responses to the online questionnaire. 
Evidence for the difference between study motivation may be observed in the difference in the 
ranges of durations reported in earlier clinical CHR-P samples (Carrión et al., 2016; Nelson et 
al., 2016; Yung et al., 2004). These showed wider ranges of longer duration closer to the YouR 
study. This similarity is not observable in the YouR study compared to more recently published 
papers (Chon et al., 2015; Zhang, et al., 2018a) . Nelson et al., (2016) proposed that the reason 
for this change over time in help seeking samples was an improvement in access to supports for 
CHR-P samples. Their study failed to find significant evidence earlier intervention as an 
explanation for the variance however (p = 0.19). 
In consideration with other findings from community samples, a different explanation for these 
difference in duration of symptoms may point to differing populations. As discussed above, this 
current study failed to replicate clinical CHR-P studies which showed duration of subthreshold 
symptoms negatively affected functional outcomes, which added to current studies which show 
community samples show lower levels of symptom severity and higher levels of functioning 
(Mills et al., 2017). The longer durations experienced by this current community sample may be 
an additional difference between community and help-seeking clinical samples, and further 
demonstrate a differing trajectory or underlying process. Research into community CHR-P 
samples are only in the preliminary stages, but the differing findings of this paper may suggest 
a need for further research to assess the significance of these differences, and illuminate the 
reasons for this divergence between samples.  
4.5 Strengths and limitations 
Three key strengths of the current study. Firstly, the YouR study is a longitudinal study 
measuring a range of outcomes of those at-risk for psychosis, and recorded both APS and BS. 
This allowed this current paper to be the first paper on DUPrS in a CHR-P sample to report on 
both duration of APS and BS in one sample.   
Secondly, the analysis conducted on the duration of APS and BS showed stable null findings 
between onset of BS compared to APS onset, suggesting that even in a moderate sized sample, 
these findings may reflect significant evidence that these is not a relationship.  
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Finally, the YouR study  is a CHR-P  sample (n = 154) recruited from a community population. 
Previous evidence on a community CHR-P sample found only 50% had shown help-seeking 
behavior (Mills et al., 2017). This suggests the participants in this study may represent a CHR-
P sample not detected in clinical studies.  
There are several limitations to the current findings. Firstly, duration was measured as a 
retroactive self-reported experience. This means the sample is vulnerable to recall bias                                
(Schultze-Lutter et al., 2010; Schultze-Lutter, Rahman, et al., 2015). This is of particular concern 
in a CHR-P sample, who are already vulnerable to cognitive deficits which might affect recall 
(Emre Bora & Murray, 2014). In addition, during data collection interviewers were not 
specifically instructed to collect estimates of duration. This meant there was missing data and 
some of the YouR CHR-P sample were excluded from analysis (APS: n = 31, BS: n = 30). A 
standardized tool or protocol in place on future studies may address this.  
Secondly, no measure of negative symptoms or nonspecific symptoms were recorded. This 
meant analysis on duration of negative symptoms could not be conducted. This is of particular 
importance in comparing this work with previous findings on the effect of DUPrS on 
functioning, where duration of negative symptoms, but not positive symptoms  have been 
identified as causing negative effect on functioning (Carrión et al., 2016). CHR-P subthreshold 
symptoms are highly heterogeneous across the population (Fusar-Poli et al., 2013), and it is 
important in future research to also use tools to measure negative and nonspecific symptoms, in 
addition to APS and BS.  
Thirdly, as this study was conducted in a CHR-P sample, a majority of whom do not transition, 
the use of prodrome does not accurately reflect the trajectory of this cohort. The decision to 
include this was based off previous CHR-P research (e.g. Nelson et al., 2016), to allow for 
comparison. However, similar to earlier models of schizophrenia which classified stages of 
schizophrenia as progressive (Lieberman et al., 2001), language in research is important in how 
it shapes understanding, and there is a need to adjust the terminology used. Future research would 
be better suited to referring to DUPrS as duration of subthreshold symptoms, or other terms 
which more fully encompass the differing trajectories of symproms for CHR-P.  
In terms of evaluating the significance of the findings, the sample who reported both APS and 
BS symptoms was small (n = 64), but only slightly smaller than the previous study on this 
question (n = 79; Schultze-Lutter et al., 2010). This suggests there is some validity in interpreting 
the analysis of the whole group which showed non-significance. In interpretation of between 
group differences, the study reports on some small group sizes. In particular the size of the 
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samples becomes significant in interpreting the findings on long BS duration. In this subgroup 
there was a significant effect, with to BS onset preceding APS onset (M.D = 1.3 months, p = 
0.04). This sample only includes 8 data points, making conclusions from this sample less 
reliable. In addition, while the robust regression analysis of this measure also reported significant 
results (B = 0.31, p = 0.002), this measure downweights outliers. All data points in this analysis 
had already been converted to z-scores to account for outliers, meaning that significant variation 
in a small sample had been removed before this significant result was found. This all suggests 
that this finding provides limited evidence for any effect.  
Comparison with other studies appears to be potentially limited, for three reasons. Firstly, the 
sample had a significant gender imbalance, and had significantly more female participants 
compared to male participants. One reason may be the pool the subjects were collected from also 
had a gender imbalance, one of the main recruitment sites for the YouR study, University of 
Glasgow,  reports a 41% male undergraduate population (Scottish Funding Council, 2017). A 
second explanation may be a difference between genders in response to the digital recruitment 
method, with female participants showing more willingness to engage with the website. Previous 
studies on e-health services had noted a higher usage among women compared to men (Smail-
Crevier et al., 2019). This is an important variable that should be accounted for in future research, 
and there is a need for research focusing on male engagement with online mental e-health.  
A second limitation of comparing this study to other measures is the high level of functioning in 
the sample. Recruiting and performing baseline assessments of functioning primarily from a 
currently studying 3rd level cohort is at risk for a sample bias towards high functioning 
individuals. This is different from other clinical cohorts, who do not primarily recruit in this way 
and may find CHR-P with lower functioning as a result. This becomes significant in both the 
reported functioning, and scores in cognition. Cognitive deficits have been shown to be 
associated with worse functional outcomes (Carrión et al., 2013). This may mean the current 
sample being high functioning also indicates lower levels of cognitive deficits than would be 
found in clinical CHR-P samples. Previous studies on the YouR dataset did observe decreased 
levels of functioning and cognition compared to controls (Haining et al., 2019), but higher the 
clinical samples. This suggests that while the presence of subthreshold symptoms does appear 
to be related to lower levels of functioning and cognition in a community sample, these findings 
may not be directly comparable. Replication of these current findings in a community sample 
that is not predominantly in 3rd level education might address these functioning and cognition 
disparities.  
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Finally the YouR study has a significantly lower transition rate (≈7%), compared to the average 
of previously reported findings  (22%; Fusar-Poli et al., 2012). This raises questions of if the 
CHR-P sample recruited from the community sample are actually at significant risk for 
psychosis, or comparable to clinical samples. Previous studies on community samples have 
noted the cohort have less severe positive, negative and general symptoms, and higher 
functioning scores compared to clinical samples (Mills et al., 2017). This suggests there is a risk 
for a between group difference of vulnerability for transition to psychosis between the YouR 
study and other clinical studies. This is significant in assessing the difference in the findings of 
the current research with previous research on BS compared to APS onset, which was analyzed 
in an FEP sample (Schultze-Lutter et al., 2010). However, follow up data collection on the YouR 
study has not been completed, and 2 year follow up is showing an increasing transition rate. 
Further follow-up data are still required for our cohort of CHR-P participants to determine who 
will develop psychosis. Preliminary evidence the persistence of APS in our sample suggest that 
the clinical trajectories may be similar to existing CHR-P samples. In addition, the frequency 
and severity of reported symptoms in this sample are comparable to clinical CHR-P samples, 
and dissimilar to general population psychotic experiences, which generally only occur between 
1 – 5 times during a lifetime (Kelleher & Cannon, 2011). This suggests that while these samples 
may not be direct comparisons, there are sufficient similarities between groups to classify this 
community sample as CHR-P.  
4.6 Future research 
There is a need for more standardization between studies of DUPrS on CHR-P populations. 
Studies currently differ on screening methods, and length of follow up on CHR-P samples (Beck 
et al., 2019; Powers et al., 2019). A specific tool designed to assertion DUPrS of symptoms in 
CHR-P, or an addition of duration as a standardized measure to current screening methods of  
sub-threshold symptoms (e.g. CAARM;   Yung et al., 2005)  would allow for more research to 
be conducted in larger samples for the effect of DUPrS on outcomes. Analysis of DUPrS in this 
way could be particularly utilized in studies on younger populations. These studies might 
produce more accurate recall of symptom onset, and if followed up could act as a prospective 
study of onset of later symptoms, rather than exclusively a retrospective study that is the standard 
in analyzing DUPrS currently. 
Very few studies currently collect data on BS duration (Fusar-Poli et al., 2009; Klosterkötter et 
al., 2001), and this current study is the first to report on duration both APS and BS duration in 
one population. Evidence shows that presence of both APS and BS increases risk for transition  
(Schultze-Lutter, Michel, et al., 2015), a frequently measured outcome in DUPrS research 
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(Carrión et al., 2013; Chon et al., 2015; Nelson et al., 2016; Yung et al., 2004; Zhang et al., 2017; 
2018b). Future research which measured BS could potentially find evidence regarding the role 
of BS duration on risk of transition. This approach to future research could also help clarify the 
findings of the current study. The findings of this study failed to replicate the previously reported 
findings of BS onset occurring prior to APS (Schultze-Lutter et al., 2010), which could have 
significant implications for several key hypotheses about sub-threshold symptoms in CHR-P . 
Larger studies of clinical and non-help seeking CHR-P samples which collect duration on both 
APS and BS data could lend clarity to the differences between the previously reported findings 
and the findings of this papers.  
The current study found a significant number of participants (37.5%, n = 24) who reported APS 
symptom prior to BS onset. There is a need for research focused on participants who report these 
findings. Larger sample sizes comparing between group differences of those who report APS 
onset preceding BS, compared to those who report BS onset preceding APS onset, might offer 
significant avenues in determining the role of BS in underlying neurobiological processes. In 
particular, studies measuring differences in transition rates and utilizing neuroimaging data 
might provide significant information in determining how these different reported patterns of 
symptom onset occur.   
This study found a longer duration of CHR-P compared to previously reported lengths found in 
clinical samples. Further research is needed on community CHR-P samples, to observe if they 
represent a sample who are undetected but at risk for transition, or if there is a larger than 
previously assumed number of individuals who experience APS and/or BS, but are not at risk 
for transition to psychosis. In particular, there is a need to assess the effect of sub-threshold 
symptoms on this sample. 
The current study found that despite significant duration lengths reported by the participants, 
that duration did not play a significant role in functioning outcomes or cognition measures. 
However, this sample still showed lower levels of functioning and poorer performance on 
cognition measures (Haining et al., 2019). There is a need for further research into what aspect 
of these sub-threshold symptoms results in these worse outcomes, if the continued length of 
symptoms does not appear to have a significant effect. 
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4.7 Conclusions  
The current research offers interesting preliminary findings into the value of studying duration 
of prodromal symptoms. The most significant evidence was found in the failure to confirm a 
hypothesis of APS as secondary outcomes to the neurobiological changes that are 
symptomatically shown in BS onset (Huber & Gross, 1989; Schultze‐Lutter & Theodoridou, 
2017; Schultze-Lutter, 2009; Schultze-Lutter et al., 2016). This finding demonstrates a need for 
further research in this area on a CHR-P sample to further validate either the present study, or 
the previous findings which did find evidence for the hypothesis (Schultze-Lutter et al., 2010). 
Answering the questions produced by this paper with regards to the validity of the hypothesis 
could yield significant findings in future CHR-P research.  
The lack of significant findings on the effect of duration of APS and BS on functioning and 
cognition also produces interesting evidence. These findings appear to add additional validity to 
hypothesized theories of a critical period of psychosis (Birchwood et al., 1998), and the 
neurodevelopmental theory of schizophrenia (McGrath et al., 2003). Both theories are dependent 
on measures of duration to validate the assumptions of the theory, but currently few studies have 
been conducted to validate them within the prodromal period.  
The difference in duration between non-help seeking CHR-P samples and previously reported 
help-seeking CHR-P samples produces interesting evidence that there may be differences 
between these samples beyond recruitment methods. This is supported by the differing findings 
on the effect of duration of subthreshold symptoms on functioning in this sample compared to 
clinical samples. Research explaining these differences is currently limited, but this study offers 
preliminary evidence that beyond symptom severity, there may be different trajectories in non-
help seeking CHR-P samples.  
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Appendices  
Appendix table 1.  
List of all symptoms and duration of symptoms reported by participants in the YouR study.  
 
Number of 
participants 
Mean 
duration, 
in months 
Median 
duration, 
in months 
Mean 
age at 
onset, in 
years 
Gender 
f(%) 
APS       
Unusual thought content  38 29.5  24 18.07 28(73.3) 
Non-bizarre ideas 63 44.52 27 18.15 47(74.6) 
Perceptual abnormalities 59 26.8 12 18.63 43(72.88) 
Disorganised speech 6 39.5 43 17.54 2(33.33) 
BS      
Inability to divide 
attention  
21 22.24 12 18.91 14(66.67) 
Thought interference  5 31 47 17.82 3(60) 
Thought blockage  34 56.21 36 17.61 23(67.65) 
Disturbances in receptive 
speech  
17 25.53 24 17.17 15(88.23) 
Disturbances in expressive 
speech  
26 35.35 21 19.21 17(65.38) 
Thought pressure  9 62.22 52 17.74 8(88.89) 
Unstable ideas of 
reference  
6 49.17 42 16.57 3(50) 
Thought perseveration  3 52.67 62 15.61 3(100) 
Decreased ability to 
discriminate.. 
9 51.33 55 14.17 4(44.44) 
Captivation of attention 
by details.. 
5 23.8 24 15.62 4(80) 
Derealization  15 47.33 42 13.39 11(73.33) 
Visual perception 
disturbances 
23 36 18 17.26 15(65.22) 
Acoustic perception 
disturbances 
30 41.5 35 17.64 21(70) 
Abbreviations APS = attenuated psychotic symptom, BS = basic symptoms, Captivation of attention by details.. = Captivation of attention 
by details in the visual field, Decreased ability to discriminate.. = Decreased ability to discriminate between ideas and perception, fantasy 
and true memories 
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Appendix table 2.  
Table of the effect of gender/age of onset on functional outcomes.  
Table 2.1 Effect of gender on functioning outcomes.  
  
B SE β t R2 p 
APS 
       
 GAF 2.440 2.450 0.096 1 0.00917 0.32 
 GF:Role 1.000 0.577 - 1.73 - 0.09 
 GF:Social 0.000 0.450 - 0.00 - 1.0 
BS        
 GAF 3.721 0.137 2.903 1.28 0.00436 0.20 
 GF:Role 1.000 0.547 - 1.83 - 0.07 
 GF:Social 0.000 0.530 - 0.00 - 1.0 
 
 
Table 2.2. Effect of age of onset on functioning outcomes.  
  
B SE β t R2 p 
APS 
       
 GAF -0.015 0.023 0.223 -0.64 0.0039 0.52 
 GF:Role 0.000 0.004 - 0.00 - 1.0 
 GF:Social 0.000 0.002 - 0.00 - 1.0 
BS        
 GAF 0.000 0.015 0.003 0.14 0.0002 0.89 
 GF:Role 0.000 0.004 - 0.00 - 1.0 
 GF:Social 0.000 0.003 - 0.00 - 1.0 
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Appendix table 3.  
The effects of duration and gender/duration and onset of APS and BS on GAF scores 
  B SE β t p R2 P 
APS        
 Duration -0.027 0.034 -0.115 -0.8 0.42   
 Gender 0.983 3.281 0.039 0.3 0.77 0.0152 0.655 
 Duration*Gender 0.028 0.046 0.097 0.61 0.55   
         
 Duration 0.005 0.064 0.022 0.08 0.94   
 Onset 0.599 0.299 0.262 2 0.05 0.0574 0.101 
 Duration*Onset 0.001 0.005 0.075 0.32 0.75   
BS        
 Duration -0.056 -0.195 0.056 -1 0.32   
 Gender 1.971 0.073 4.602 0.43 0.67 0.0352 0.387 
 Duration*Gender 0.032 0.110 0.067 0.47 0.64   
         
 Duration 0.036 0.126 0.093 0.39 0.70   
 Onset 0.636 0.248 0.475 1.34 0.18 0.0406 0.32 
 Duration*Onset -0.003 -0.149 0.005 -0.54 0.59   
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Appendix table 4.  
Table of the effect of gender/age of onset on functional outcomes, samples divided into short 
and long duration.  
Table 4.1 Effect of gender on functioning outcomes. 
  
B SE β t R2 p 
APS 
      
Short       
 GAF 0.086 2.279 0.004 0.03 0.0000 0.98 
 GF:Role 0 0.78 - 0 - 1.0 
 GF:Social 0 0.019 - 0.00 - 1.0 
Long       
 GAF 4.240 3.550 0.162 1.19 0.0261 0.24 
 GF:Role 1 0.61 - 1.63 - 0.11 
 GF:Social 0 0.059 - 0 - 1.0 
BS       
Short       
 GAF 2.010 4.700 0.066 0.43 0.0044 0.67 
 GF:Role -1 0.69 - -1.44 - 0.16 
 GF:Social 0.000 0.41 - 0.00 - 1.0 
Long        
 GAF 5.430 3.470 0.235 1.57 0.0552 0.12 
 GF:Role 1 0.449 - 2.226 - 0.032 
 GF:Social 1 0.56 - 1.8 - 0.08 
 
 
Table 4.2. Effect of age of onset on functioning outcomes. 
 
  
B SE β t R2 p 
APS 
      
Short       
 GAF 0.232 0.329 0.097 0.7 0.0094 0.48 
 GF:Role 0 0.051 - 0.00 - 1.0 
 GF:Social 0.000 0.019 - 0.00 - 1.0 
Long       
 GAF 0.808 0.376 0.284 2.15 0.0804 0.036 
 GF:Role -0.051 0.053 - -0.95 - 0.34 
 GF:Social 0 0.059 - 0.00 - 1.0 
BS       
Short       
 GAF -0.305 0.201 -0.228 -1.51 0.0518 0.14 
 GF:Role -0.071 0.056 - -1.275 - 0.21 
 GF:Social 0 0.041 - 0.00 - 1.0 
Long       
 GAF -0.014 0.040 -0.056 -0.36 0.0031 0.72 
 GF:Role 1.000 0.059 - 0.00 - 1.0 
 GF:Social 0.000 0.055 - 0.00 - 1.0 
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Appendix table 5 
linear regressions of the effect of gender/age of onset on neurocognitive outcomes.  
Appendix table 5.1  
Table of effect of gender on cognition 
   
B SE t R2 p 
APS      
 BACS       
  Verbal memory -0.078 0.260 -0.3 0.0009 0.77 
  Working memory 0.654 0.274 2.38 0.0559 0.02 
  Motor speed -0.084 0.257 -0.33 0.0011 0.75 
  Attention & processing speed 0.608 0.252 2.42 0.0574 0.02 
  Verbal fluency 0.957 0.083 11.6 0.5830 < 0.0001 
  Executive function 0.035 0.305 0.11 0.0001 0.91 
  BACS composite score 0.747 0.321 2.33 0.0536 0.02 
 Penn CNP      
  Emotion recognition accuracy  0.440 0.208 2.11 0.0445 0.04 
  Emotion recognition RT -0.267 0.274 -0.97 0.0098 0.33 
  Attention accuracy  0.099 0.294 0.34 0.0012 0.74 
  Attention RT 0.218 0.196 1.11 0.0127 0.27 
  Working memory accuracy 0.063 0.264 0.24 0.0575 0.81 
  Working memory RT  0.082 0.185 0.44 0.0021 0.66 
BS      
 BACS       
  Verbal memory 0.024 0.435 0.05 0.0000 0.96 
  Working memory 0.252 0.378 0.67 0.0122 0.51 
  Motor speed 0.218 0.398 0.55 0.0082 0.59 
  Attention & processing speed 0.432 0.388 1.11 0.0333 0.27 
  Verbal fluency 1.073 0.151 7.09 0.583 < 0.0001 
  Executive function -0.239 0.524 -0.46 0.0058 0.65 
  BACS composite score 0.452 0.468 0.96 0.0252 0.34 
 Penn CNP      
  Emotion recognition accuracy  0.481 0.220 1.99 0.0485 0.05 
  Emotion recognition RT -0.239 -0.084 -0.74 0.0070 0.46 
  Attention accuracy  0.432 0.154 1.38 0.0239 0.17 
  Attention RT -0.192 -0.085 -0.52 0.0071 0.61 
  Working memory accuracy 0.279 0.107 0.95 0.0115 0.34 
  Working memory RT  0.047 0.025 0.22 0.0006 0.83 
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Appendix table 5.2 
Table of effect of age of onset on cognition  
   
B SE t R2 p 
APS      
 BACS       
  Verbal memory 0.063 0.023 2.75 0.0732 0.01 
  Working memory 0.100 0.030 3.35 0.1110 0.001 
  Motor speed 0.007 0.023 0.31 0.0010 0.76 
  Attention & processing speed -0.005 0.024 -0.19 0.0004 0.85 
  Verbal fluency -0.003 0.012 -0.29 0.0009 0.77 
  Executive function -0.021 0.028 -0.75 0.0058 0.46 
  BACS composite score 0.018 0.030 0.59 0.0037 0.55 
 Penn CNP      
  Emotion recognition accuracy  -0.005 0.020 -0.27 0.0008 0.79 
  Emotion recognition RT 0.200 0.025 0.79 0.0065 0.43 
  Attention accuracy  0.047 0.027 1.75 0.0308 0.08 
  Attention RT 0.007 0.018 0.4 0.0017 0.69 
  Working memory accuracy 0.008 0.024 0.31 0.0010 0.76 
  Working memory RT  0.028 0.017 1.65 0.0277 0.10 
BS      
 BACS       
  Verbal memory 0.109 0.047 2.29 0.128 0.03 
  Working memory -0.010 0.044 -0.22 0.00134 0.83 
  Motor speed -0.084 0.045 -1.88 0.089 0.07 
  Attention & processing speed -0.013 0.046 -0.29 0.00235 0.77 
  Verbal fluency 0.014 0.027 0.53 0.0076 0.60 
  Executive function -0.045 0.061 -0.74 0.015 0.46 
  BACS composite score -0.028 0.055 -0.51 0.00709 0.62 
 Penn CNP      
  Emotion recognition accuracy  0.000 0.002 0.02 0.0000 0.99 
  Emotion recognition RT 0.074 0.282 2.59 0.0795 0.01 
  Attention accuracy  0.022 0.087 0.77 0.0076 0.44 
  Attention RT 0.027 0.099 0.6 0.0097 0.55 
  Working memory accuracy -0.021 -0.090 -0.79 0.0080 0.43 
  Working memory RT  0.027 0.152 1.36 0.0232 0.18 
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Appendix table 6 
The effect of duration and gender/duration and age of onset on cognition measures  
Appendix table 6.1  
Multivariate regression of the effect of APS duration and gender on cognition measures. 
   B SE t Pr(>|t|) R2 p 
BACS        
 Verbal memory       
  Duration 0.002 0.003 0.61 0.54   
  Gender 0.124 0.349 0.36 0.72 0.0094 0.83 
  Duration*Gender -0.004 0.005 -0.9 0.37   
 Working memory       
  Duration 0.006 0.004 1.56 0.12   
  Gender 0.993 0.364 2.73 0.01 0.0802 0.05 
  Duration*Gender -0.006 0.005 -1.28 0.20   
 Motor speed       
  Duration -0.002 0.003 -0.6 0.55   
  Gender 0.094 0.336 0.28 0.78 0.0555 0.15 
  Duration*Gender -0.005 0.005 -1.15 0.25   
 Attention and processing speed       
  Duration 0.000 0.003 -0.05 0.96   
  Gender 0.613 0.338 1.81 0.07 0.0575 0.13 
  Duration*Gender 0.000 0.005 -0.04 0.97   
 Verbal fluency       
  Duration -0.001 0.001 -0.66 0.51   
  Gender 0.918 0.111 8.29 0.00 0.5850 < 0.0001 
  Duration*Gender 0.001 0.002 0.47 0.64   
  Executive function       
  Duration 0.003 0.004 0.66 0.51   
  Gender 0.247 0.409 0.6 0.55 0.0067 0.89 
  Duration*Gender -0.004 0.006 -0.77 0.44   
 BACS composite score       
  Duration 0.003 0.004 0.75 0.46   
  Gender 1.067 0.428 2.49 0.01 0.0673 0.09 
  Duration*Gender -0.007 0.006 -1.17 0.25   
PennCNP       
 Emotion recognition accuracy        
  Duration 0.000 0.003 0.06 0.95   
  Gender 0.361 0.279 1.29 0.20 0.0515 0.17 
  Duration*Gender 0.002 0.004 0.54 0.59   
 Emotion recognition RT       
  Duration 0.001 0.004 0.36 0.72   
  Gender -0.362 0.365 -0.99 0.32 0.0255 0.49 
  Duration*Gender 0.003 0.005 0.57 0.57   
 Attention accuracy        
  Duration 0.003 0.004 0.83 0.41   
  Gender 0.426 0.392 1.09 0.28 0.0190 0.61 
  Duration*Gender -0.007 0.006 -1.3 0.20   
 Attention RT       
  Duration -0.003 0.003 -1.24 0.22   
  Gender 0.141 0.261 0.54 0.59 0.0378 0.30 
  Duration*Gender 0.001 0.004 0.21 0.84   
 Working memory accuracy       
  Duration 0.000 0.004 -0.05 0.96   
  Gender 0.191 0.353 0.54 0.59 0.0111 0.79 
  Duration*Gender -0.003 0.005 -0.67 0.51   
 Working memory RT        
  Duration 0.002 0.002 0.82 0.41   
  Gender 0.323 0.245 1.32 0.19 0.0296 0.42 
  Duration*Gender -0.005 0.003 -1.58 0.12   
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Appendix table 6.2 
Multivariate regression of the effect of BS duration and gender on neurocognitive outcomes. 
   B SE t Pr(>|t|) R2 p 
BACS        
 Verbal memory       
  Duration 0.002 0.003 0.61 0.54   
  Gender 0.124 0.349 0.36 0.72 0.0094 0.83 
  Duration*Gender -0.004 0.005 -0.9 0.37   
 Working memory       
  Duration 0.006 0.004 1.56 0.12   
  Gender 0.993 0.364 2.73 0.01 0.0802 0.05 
  Duration*Gender -0.006 0.005 -1.28 0.20   
 Motor speed       
  Duration -0.002 0.003 -0.6 0.55   
  Gender 0.094 0.336 0.28 0.78 0.0555 0.15 
  Duration*Gender -0.005 0.005 -1.15 0.25   
 Attention and processing speed       
  Duration 0.000 0.003 -0.05 0.96   
  Gender 0.613 0.338 1.81 0.07 0.0575 0.13 
  Duration*Gender 0.000 0.005 -0.04 0.97   
 Verbal fluency       
  Duration -0.001 0.001 -0.66 0.51   
  Gender 0.918 0.111 8.29 0.00 0.5850 < 0.0001 
  Duration*Gender 0.001 0.002 0.47 0.64   
 Executive function       
  Duration 0.003 0.004 0.66 0.51   
  Gender 0.247 0.409 0.6 0.55 0.0067 0.89 
  Duration*Gender -0.004 0.006 -0.77 0.44   
 BACS composite score       
  Duration 0.003 0.004 0.75 0.46   
  Gender 1.067 0.428 2.49 0.01 0.0673 0.09 
  Duration*Gender -0.007 0.006 -1.17 0.25   
PennCNP       
 Emotion recognition accuracy        
  Duration -0.002 -0.090 -0.44 0.66   
  Gender 0.350 0.160 0.91 0.37 0.0511 0.26 
  Duration*Gender 0.002 0.106 0.44 0.66   
 Emotion recognition RT       
  Duration 0.004 0.123 0.6 0.55   
  Gender 0.291 0.102 0.58 0.57 0.0428 0.34 
  Duration*Gender -0.010 -0.334 -1.37 0.17   
 Attention accuracy        
  Duration 0.001 0.037 0.18 0.86   
  Gender 0.329 0.118 0.66 0.51 0.0320 0.48 
  Duration*Gender 0.002 0.068 0.28 0.78   
 Attention RT       
  Duration -0.033 -0.321 -1.29 0.21   
  Gender -0.638 -0.281 -0.82 0.42 0.0567 0.56 
  Duration*Gender 0.024 0.274 0.69 0.50   
 Working memory accuracy       
  Duration -0.011 -0.395 -1.96 0.05   
  Gender -0.388 -0.149 -0.85 0.40 0.0613 0.18 
  Duration*Gender 0.012 0.453 1.88 0.06   
 Working memory RT        
  Duration -0.003 -0.147 -0.71 0.48   
  Gender -0.105 -0.054 -0.3 0.76 0.0073 0.91 
  Duration*Gender 0.003 0.138 0.56 0.58   
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Appendix table 6.3 
Multivariate regression of the effect of APS duration and age of onset on neurocognitive 
outcomes. 
   B SE t Pr(>|t|) R2 p 
BACS        
 Verbal memory       
  Duration 0.010 0.007 1.38 0.17   
  Onset 0.100 0.030 3.35 0.00 0.1110 0.01 
  Duration*Onset 0.000 0.001 -0.73 0.46   
 Working memory       
  Duration 0.011 0.008 1.29 0.20   
  Onset 0.049 0.034 1.43 0.16 0.0258 0.48 
  Duration*Onset -0.001 0.001 -0.95 0.34   
 Motor speed       
  Duration 0.008 0.007 1.02 0.31   
  Onset -0.001 0.030 -0.02 0.98 0.0854 0.04 
  Duration*Onset -0.001 0.001 -1.98 0.05   
 Attention and processing speed       
  Duration 0.012 0.008 1.53 0.13   
  Onset 0.010 0.031 0.33 0.74 0.0424 0.25 
  Duration*Onset -0.001 0.001 -1.92 0.06   
 Verbal fluency       
  Duration -0.007 0.004 -2.02 0.05   
  Onset -0.027 0.015 -1.77 0.08 0.0563 0.14 
  Duration*Onset 0.000 0.000 1.42 0.16   
 Executive function       
  Duration 0.011 0.009 1.18 0.24   
  Onset -0.005 0.037 -0.13 0.89 0.0271 0.46 
  Duration*Onset -0.001 0.001 -1.4 0.17   
 BACS composite score       
  Duration 0.016 0.010 1.69 0.09   
  Onset 0.046 0.039 1.18 0.24 0.0399 0.28 
  Duration*Onset -0.001 0.001 -1.18 0.24   
PennCNP       
 Emotion recognition accuracy        
  Duration 0.004 0.006 0.62 0.54   
  Onset 0.004 0.026 0.16 0.87 0.0048 0.93 
  Duration*Onset 0.000 0.000 -0.58 0.57   
 Emotion recognition RT       
  Duration 0.006 0.008 0.74 0.46   
  Onset 0.054 0.033 1.62 0.11 0.0476 0.20 
  Duration*Onset 0.000 0.001 0.01 0.99   
 Attention accuracy        
  Duration 0.007 0.009 0.84 0.40   
  Onset 0.072 0.036 2.01 0.05 0.0428 0.25 
  Duration*Onset 0.000 0.001 -0.52 0.60   
 Attention RT       
  Duration -0.005 0.006 -0.78 0.44   
  Onset -0.015 0.024 -0.64 0.53 0.0335 0.36 
  Duration*Onset 0.000 0.000 0.13 0.90   
 Working memory accuracy       
  Duration 0.006 0.008 0.75 0.45   
  Onset 0.011 0.032 0.34 0.74 0.0190 0.61 
  Duration*Onset -0.001 0.001 -1.1 0.27   
 Working memory RT        
  Duration 0.001 0.005 0.25 0.80   
  Onset 0.034 0.023 1.52 0.13 0.0305 0.40 
  Duration*Onset 0.000 0.000 -0.06 0.95   
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Appendix table 6.4 
Multivariate regression of the effect of BS duration and age of onset on neurocognitive 
outcomes. 
   B SE t Pr(>|t|) R2 p 
BACS        
 Verbal memory       
  Duration 0.010 0.007 1.38 0.17   
  Onset 0.100 0.030 3.35 0.00 0.1110 0.01 
  Duration*Onset 0.000 0.001 -0.73 0.46   
 Working memory       
  Duration 0.011 0.008 1.29 0.20   
  Onset 0.049 0.034 1.43 0.16 0.0258 0.48 
  Duration*Onset -0.001 0.001 -0.95 0.34   
 Motor speed       
  Duration 0.008 0.007 1.02 0.31   
  Onset -0.001 0.030 -0.02 0.98 0.0854 0.04 
  Duration*Onset -0.001 0.001 -1.98 0.05   
 Attention and processing speed       
  Duration 0.012 0.008 1.53 0.13   
  Onset 0.010 0.031 0.33 0.74 0.0424 0.25 
  Duration*Onset -0.001 0.001 -1.92 0.06   
 Verbal fluency       
  Duration -0.007 0.004 -2.02 0.05   
  Onset -0.027 0.015 -1.77 0.08 0.0563 0.14 
  Duration*Onset 0.000 0.000 1.42 0.16   
 Executive function       
  Duration 0.011 0.009 1.18 0.24   
  Onset -0.005 0.037 -0.13 0.89 0.0271 0.46 
  Duration*Onset -0.001 0.001 -1.4 0.17   
 BACS composite score       
  Duration 0.016 0.010 1.69 0.09   
  Onset 0.046 0.039 1.18 0.24 0.0399 0.28 
  Duration*Onset -0.001 0.001 -1.18 0.24   
PennCNP       
 Emotion recognition accuracy        
  Duration 0.006 0.248 0.72 0.40   
  Onset 0.023 0.117 0.59 0.56 0.0103 0.85 
  Duration*Onset 0.000 -0.256 -0.87 0.39   
 Emotion recognition RT       
  Duration -0.004 -0.151 -0.46 0.65   
  Onset 0.056 0.213 1.11 0.27 0.0863 0.075 
  Duration*Onset 0.000 0.185 0.65 0.52   
 Attention accuracy        
  Duration 0.008 0.287 0.85 0.40   
  Onset 0.059 0.229 1.16 0.25 0.0307 0.5 
  Duration*Onset 0.000 -0.109 2   -0.37 0.71   
 Attention RT       
  Duration 0.007 0.068 0.09 0.90   
  Onset 0.044 0.161 0.45 0.65 0.0446 0.66 
  Duration*Onset -0.001 -0.256 -0.34 0.74   
 Working memory accuracy       
  Duration 0.001 0.027 0.08 0.94   
  Onset -0.020 -0.084 -0.42 0.67 0.0347 0.44 
  Duration*Onset 0.000 -0.185 -0.64 0.53   
 Working memory RT        
  Duration -0.001 -0.034 -0.1 0.92   
  Onset 0.024 0.138 0.7 0.49 0.0248 0.59 
  Duration*Onset 0.000 0.065 0.22 0.82   
 
